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Abstract 
The 1 H and nc solution-state NMR spectra of the three studied drug molecules 
(indomethacin, nifedipine and carbamazepine) were fully assigned. This led to the 
characterisation and assignment of the 13C CPMAS SSNMR spectra of the stable 
polymorphic forms of these molecules. The signal for the C-CI carbon of 
indomethacin has been studied as a function of applied magnetic field, and the 
observed bandshapes have been simulated. A T1H and T1pH study was undertaken on 
the crystalline materials, as well as on the quench-cooled amorphous and PVP/drug 
co-melts. This was done in order to fulfil the aim of this research, i.e. to understand 
the difference in stability of the amorphous compounds and also to investigate the 
effect of the presence of PVP on the stability and mobility of the drug. It was shown 
that, under the conditions of the experiments, amorphous indomethacin did not 
recrystallise until ll0°C, whilst in the case of nifedipine and carbamazepine the 
recrystallisation occurred at 70°C and 75°C respectively. It was also shown that in 
the case of the co-melts a transition occurs consistently between 65°C and 85°C for 
the three materials and this seems to be due to the Tg of the co-melts. The 
comparison of the T 1 H and T 1 PH data for the different states showed that 
amorphisation increased the mobility of the sample, this being more pronounced for 
carbamazepine and nifedipine than for indomethacin, and also that the co-melts were 
more stable and slightly more mobile than the amorphous compounds. The 
comparison of the relaxation data between the pure compounds showed that 
amorphous indomethacin was more stable than the other two amorphous drugs as 
slope changes occurred for the latter at a temperature below Tg, whilst this happens 
at or around Tg for amorphous indomethacin. 
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Chapter One: Introduction 
Chapter One: Introduction 
11 Solid-State Nuclear Magnetic Resonance (SSNMR)1 
The main differences between SSNMR and solution-state NMR results from the 
general absence of rapid molecular motion. This lack of molecular motion implies 
the presence of two parameters that complicate the spectra. These two parameters 
are: 
- Dipole-dipole interactions. 
- Chemical Shift Anisotropy (CSA). 
These parameters will be detailed in later sections. 
In the presence of a liquid, we do not see the effects of these kinds of interaction 
directly because the molecules are tumbling rapidly. Therefore, these parameters, 
which are orientation dependent, are averaged to their isotropic values. Different 
techniques have been produced to help in reducing the broad lines created for solids 
by the above parameters. They are: 
- Magic-Angle Spinning (MAS). 
- High-power proton decoupling. 
These techniques will be discussed in the following sections. 
1.1/ Dipole-dipole interactions 
This interaction involves pairs of nuclear spin dipoles, i.e. two spins, which interact 
through space. In solid-state NMR, this interaction is not generally averaged, and it 
can have values of tens to hundreds of kilohertz. 
If one considers an isolated pair of different spins, AX, one will have an energy 
equation (to first order) of the form: 
Equation 1.1 
and Yx are the appropriate Larmor frequencies, rnA and mx are the appropriate 
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quantum numbers, Bo is the magnetic field of the spectrometer, YA and 'Yx are the 
appropriate magnetogyric ratios and r is the distance between the two spins. 
From equation 1.1, it is seen that the dipole-dipole interaction depends on the 
orientation of the system and also on the distance separating the two dipoles. Thence, 
the powder pattern (also known as a Pake doublet) of the system (figure 1.1) can be 
determined, i.e. the spectrum for a microcrystalline powder containing particles with 
all possible orientations of the inter-dipole distance. 
R 6 
Figure 1.1: Representation of a heteronuclear dipolar powder pattern for an isolated 
AX system. Only the A part of the AX system is shown, the X part being identical. 
1.2/ Chemical shift anisotropy 
This interaction also depends on the orientation of the molecule. Therefore, it will 
not appear for a liquid sample because the rapid tumbling averages it to zero and so 
only the isotropic chemical shift affects the spectrum. This interaction works in the 
three dimensions, so we have three principal components to the shielding tensor (cr 11 , 
cr22 and cr33). Nevertheless, this interaction also depends on the symmetry of the 
studied molecule as shown in figure 1.2 which illustrates powder patterns for 
chemical shifts. 
2 
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(a) 
---","----
0";!0(1 
(b) 
I 
CI;; 
Figure 1.2: Schematic powder pattern caused by shielding anisotropy for isolated 
spins with site of (a) cubic symmetry (isotropic case) (b) axial symmetry, and (c) low 
symmetry. 
For the case of cubic symmetry, e.g. Be in the molecule CH4, all three shielding 
tensor components are equal: 
Equation 1.2 
For an axially symmetric case (e.g. Be in the molecule CHCh), we have two 
principal orientations, giving cr1. and cr11 as shown in figure 1.3. 
Bo 
H A-CI 
Cl ~CI 
0';; O'j_ 
(two equal values) 
Figure 1.3: Axially symmetric case 
3 
Chapter One: Introduction 
In this case, the shielding anisotropy is defined as: 
~0" =(a-ll- 0" J 
The isotropic shielding is: 
Equation 1.3 
Equation 1.4 
This value will be slightly different between the solid and solution states. In the 
latter, only the isotropic shielding affects the spectrum. 
For the general case, there are three tensor elements labelled: 
where CJiso is the isotropic chemical shift defined as follow: 
The shielding anisotropy is referred to as: 
Or, alternatively: 
Note that: ~a-= 3S 
2 
The shielding asymmetry, 11. is defined as: 
Equation 1.5 
Equation 1.6 
Equation 1. 7 
Equation 1.8 
Equation 1.9 
1.3/ Magic-angle spinning and high-power proton decoupling 
The shielding anisotropy and the dipole-dipole coupling interactions are dependent 
on the orientation of the molecule, expressed by the factor (3cos28 - I). Therefore, if 
it is possible to average this factor to zero, these interactions will not complicate the 
spectrum. In solution, this factor is averaged to zero by the rapid molecular tumbling 
of the molecule, which explains the very narrow peaks observed in solution-state 
NMR. 
If one consider a solid sample spun at an angle f3 to B0 (figure 1.4). For a single 
crystal the angle x is fixed, which will not be true for a powder, wh_~re x s_an,J~k~=aJL,,.L .. 
• , . . __ .· _ -,,-.•·o,o·'"~'·· "---.~~~·- .. ,-- ~._.,_ '·· ••..•. _.=:=.~"';_,.'to""' •'·"'"~'"-'V·'...C'•:-!·-'I••::t,.7->".,•;h·.--~-.f~'l"'~'-~:, · r~" •·· ·· • 
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possible values. The average of (3cos28 - 1) about the conical path, indicated for the 
internuclear vector "r" in equation 1.1 0, has to be found to be: 
(3cos 2 0 -1) = _!_(3cos 2 p -1)(3cos2 X -1) 
2 
Equation 1.10 
One can see that the function Y2 (3cos213 - 1) will scale the powder patterns. 
One can also see that if 13 is 54.JO, thencosp =~,and 3cos2 p -1 = 0. Therefore, 
3 cos 2 0 - 1 = 0 for all initial orientations of r in B0• 
Figure 1.4: Spinning of a sample, represented by r, at an angle 13 in respect to Bo. 
The speed at which the sample can be spun is also important because if the sample 
does not spin quickly enough to overcome totally the effect of the shielding 
anisotropy, spinning sidebands will appear at intervals of the spin rate from the 
isotropic chemical shift (which is referred to as the centreband). These spinning 
sidebands are useful when there is interest in the parameters of the shielding tensor, 
as they will enable information about these parameters to be found. The lower the 
spinning speed, the more spinning sidebands will be observed. It should be noted that 
the centreband can be located by varying the spin rate, if necessary. 
However, one problem cannot be fully eliminated with this technique, which is the 
dipole-dipole interaction. In order to eliminate totally this kind of interaction, one 
would need to spin the sample at speed greater than the static bandwidth expressed in 
Hz. As this can be ofthe order oftens to hundreds of kHz for 13C, it is not possible to 
be achieved. However, another te.chnique has been developed called high-power 
proton decoupling. For the case of 13C-1H dipolar interactions, one just needs to 
5 
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apply r.f. pulses on the proton channel, which should be equal to or greater than the 
dipole interaction, i.e. in the order of ten's of kHz, whilst acquiring on the carbon 
channel. This is quite different from solution-state NMR as one only needs to 
decouple J, which implies a lower power. The effect of the r.f. field will be to 
decouple the proton from the carbon. As a consequence, the spectrum will be greatly 
simplified. 
1.4/ Relaxation times 
Recently, NMR relaxation times have been shown to be particularly sensitive to 
changes around the glass transition. This led to some studies in which this technique 
' 
is applied to amorphous compounds in order to investigate their molecular mobility2-
4. For solids, the proton spin-lattice relaxation time and the proton spin-lattice 
relaxation time in the rotating frame of resonance (denoted T1H and T1/ 
respectively) are generally measured. The relaxation time T1H reflects the molecular 
mobility on the timescale of the Larmor frequency (generally hundreds of MHz), 
while T1/ represents the molecular mobility on the timescale of the nutation 
frequency of the experiment, which corresponds to the strengths of the applied radio 
frequenc/. Some aspects of molecular mobility can also be investigated using 
differential scanning calorimetrl. 
As T 1 H relaxation times are in the order of seconds or tens of seconds, it is easily 
understood that the time required for measurement would be a limiting factor in 
obtaining a series of data over a wide range of temperatures. This explains why most 
of the studies done on T1H measurements do not show replicate measurements, or use 
only a narrow range of temperatures3•4'7'8. However, a few papers study T1H over a 
wide range of temperatures, but this is possible only because of a short T19- 11 . 
Another important point from the relaxation times is that the study of their variation 
over the temperature range allows one to retrieve the activation energies involved in 
the relaxation process. 
In order to obtain the activation energy, one needs to refer to the equation 1.11 12: 
Equation 1.11 
6 
Chapter One: Introduction 
where 'tc is the motional correlation time, i.e. the average time for a molecule with 
random molecular tumbling to progress through one radian, and ro is the 
spectrometer 1H frequency for T1 or the nutation frequency (yB 1/2n) for Ttp· It 
should be noted that for an activated process one should use equation 1.12: 
rc = Dexp( -Ri' J Equation 1.12 
where D is a constant. 
For the rigid side of a relaxation minimum, 'tc is long, so we have ro21"c2 >> 1. 
Therefore, from equation 1.11, we can see that T,-t is proportional to llro2.-c, i.e. T1 is 
proportional to 'tc. By applying this to equation 1.12, we get equation 1.13: 
ln(T.) =A~ _S,_ 
I RT Equation 1.13 
where A is a constant. 
Similarly, for the mobile side of the minimum, where 'tc is short, we have I >> ro2.-/. 
Therefore, from equation 1.11 we can see that T ,-t is proportional to •c· By applying 
this to equation 1.12, we get equation 1.14: 
E ln(T;)= B+-a 
RT 
where B is a constant. 
Equation 1.14 
One can then see that from the slope of the graph ln(T1) vs. 1/T, and by using 
equations 1.13 and 1.14, it is possible to obtain the activation energy. Alternatively, 
one can fit the complete curve, but this may not be satisfactory if there is partial 
overlap between different minima. 
By doing the differentiation of equation 1.11, one can see that the minimum will 
occur when: 
1 
r,. =- Equation 1.15 
OJ 
This is valid for crystalline materials as in such cases only a single specific type of 
motion appears to be involved. However, there are circumstances when meaningful 
activation energies cannot be retrieved from the slope. This can be due to the 
presence of several motions of similar activation energies. In the case of amorphous 
materials, it is likely that complications arise dtie to the fact that for any given 
motion, a range of activation energies is expected as the intermolecular interactions 
~-~ -.. ._.,, 
7 
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will vary with the environment, which is variable throughout the amorphous sample. 
In both of these cases, the situation would involve overlapping minima, giving a 
broad and shallow minimum, if any minimum is visible at all. As a result, the slopes 
would not properly reflect the activation energies. 
2/ Pulse sequences 
2.1/ Solid-state NMR 
2.1.1) Cross Polarisation (CP) 
The cross polarisation is a pulse sequence that allows the magnetisation from an 
abundant spin, generally proton nuclei, to be transferred to a dilute spin, e.g. 13C 
nuclei. The aim is to improve the sensitivity, which would otherwise be low, 
especially because of long relaxation times in solids. In order to achieve this, the 
system needs to fulfil the Hartmann-Hahn condition in the rotating frame of 
reference, that is: 
Equation 1.16 
where BIH and B1c are the strengths of the 1H and 13C radiofrequency fields 
respectively. 
This condition implies that both nuclei are precessing at the same frequency in their 
respective rotating frames of resonance. 
The CP pulse sequence is shown in figure 1.5. At first, a 90° pulse is applied at the 
proton frequency in order to place the magnetisation in the xy plane, the rotating 
frame of resonance. Then, the proton magnetisation is spin locked in the y direction. 
The second step is to switch on the r.f. at the 13C channel and to adjust B1c in order to 
fulfil the Hartmann-Hahn condition. After a suitable time (the contact time), the r.f. 
at the 13C channel is switched off and the FID recorded for this nucleus, but the r.f. is 
kept on at the 1H channel in order to eliminate the effects of the 13C-1H dipolar and 
scalar interactions. Typically, a contact time of 1 to 5 ms is used for 13C. 
This pulse sequence is used because the magnitude of the 13C signal will be 
determined by the magnetogyric ratio of the proton rather than that of the 13C. This 
difference will, in theory, increase the magnitude of the 13C signal by a factor of 
YHiyc,j,e. C\. :fustor of ca. four,~compared to a normaln/2-acquire sequence· on the 13C. 
8 
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Furthermore, as the magnetisation is coming from the protons, the delay between 
each pulse sequence is determined by the spin-lattice relaxation time of the protons 
(T 1 H), which is shorter than that of 13C. As a consequence, the pulse delay will be 
greatly reduced and thus the experimental time. 
decoupling 
Figure 1.5: The pulse sequence for a CP experiment. 
Generally, the CP pulse sequence is used with MAS, and the experiment is then 
called CPMAS. MAS is used to eliminate the shielding anisotropy and dipole-dipole 
interactions. 
2.1.2) Non-Quaternary Suppression (NQS) - also known as dipolar 
dephasing 
The NQS experiment works partly in the same way as the CP experiment. The. 
difference between the two is the insertion of a decoupling window after the contact 
time (see figure 1.6). This decoupling window allows for the elimination of the 
signals coming from the non-quaternary carbons. A carbon attached to a proton will 
have a much stronger dipolar coupling than a quaternary one (in the absence of 
decoupling). A nucleus with a strong dipolar coupling will have a shorter FID than if 
it had a weak dipolar coupling. A short FID means that if a long enough time (about 
40 to 60 J.LS), without applying a r.f. to the proton channel, is waited, then the signal 
from the non-quaternary carbons will not be seen and the signal from the quaternary 
carbons will still be present. 
However, such an experiment still shows the CH3 groups as these groups have long 
FIDs while the Cl-1 and .~H2 haye short FIDs. This_ can be explained by the rapid · 
. ' ,. , .. ~- ... " ... =-. . ·- '"f." . . .. - ~- . • --
9 
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internal rotation of a methyl group which partially averages the dipolar coupling. As 
a consequence, the dipolar coupling is relatively weak and this means a long FID. 
Therefore, the CH3 signal is also retained but with a lower intensity compared to a 
normal CP experiment. 
couplinr window 
lH 90ox Y Y 
r-------~--------~ 
decoupling 
contact 
I:t coupled decay 
Figure 1.6: The pulse sequence for a NQS experiment. 
2.1.3) T1H experiment 
Measuring T 1 H for indomethacin and nifedipine was done using a saturation-recovery 
experiment (figure 1.7). This pulse sequence consists of a series of around one 
hundred 90° pulses, each of a few microsecond duration, which are separated by a 
typical time of around 100 JlS; these pulses are used to saturate the signal. Then, a 
recovery time (-r) is waited in order to regain some of the magnetisation. This is then 
followed by a 90° pulse to put the magnetisation into the y direction so as to allow 
the acquisition of a signal. The time -r is arrayed in order to have a series of spectra 
that will provide data which can be fitted into equation 1.17. 
Equation 1.17 
where "amp" represents the intrinsic amplitude of the peak. However, some of the 
results were fitted to a double exponential: the equation is shown in equation 1.18. 
Equation 1.18 
where "ampa" and "ampb" represent the intrinsic amplitudes of the first and second 
exponential,respectively; ·and Tta -and Tii>'fepreseflft:tre·T~-values 'of d1e''first"im(f 
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second exponential respectively. In the case of a double exponential fit, a population 
weighted average rate was used to derive an overall value ofT1• 
Figure 1.7: The pulse sequence for a saturation-recovery experiment. 
2.1.4) T1pH experiment 
For indomethacin and nifedipine, the T1/ measurements were done using a 
spin-lock experiment (figure 1.8). This consists of a 90° pulse to rotate the 
magnetisation to the y-axis, followed by a 90° phase change of B1 to place it also in 
the y direction, thus "locking" it (i.e. slowing down its rate of decay). This situation 
is maintained for a variable time, 't (the spin-lock time), after which the spectrum is 
acquired. The spin-lock time is arrayed to get a series of spectra from which the data 
is recovered and fitted to equation 1.19. 
y = amp x exp[- r) 
Ttp 
Equation 1.19 
where "amp" represents the intrinsic amplitude of the peak. However, some of the 
results were fitted to a double exponential: the equation is shown in equation 1.20. 
y = amp a x exp[ - r ) + amp h x exp[ - r ) 
Ttpa T;pb 
Equation 1.20 
where "ampa" and "ampb" represent the intrinsic amplitudes of the first and second 
exponential respectively, and Ttpa and Ttpb represent the T1p values of the first and 
second exponential respectively. In the case of a double exponential fit, a population 
weighted average rate was used to determine the value ofTtp· 
11 
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90oX Y 
II· ' h 1\ A ~ ~ 
Figure 1.8: The pulse sequence for a spin-lock experiment. 
However, for carbamazepine the value of T1H was so long (ca. 200 s) that it was 
decided to use a saturation-recovery with the spin-lock experiment (figure 1.9) in 
order to determine the value ofT1pH· This experiment begins as a saturation-recovery 
one butt is fixed to a value of about 20% ofT1 H' then a spin-lock sequence is added. 
This version was used rather than the normal spin-lock experiment as this allows for 
a quicker recycle of the sequence and also the magnetisation is measured from a set 
point. The spin-lock time is then arrayed and the results obtained are fitted to 
equation 1.19 or equation 1.20. 
n 
Figure 1.9: Pulse sequence for saturation-recovery with the spin-lock experiment. 
2.2/ Solution-state NMR 
The experiments described below are all 2D experiments. Such experiments require 
two waiting times, generally called t1 and t2• Thus, we are presented with a 2D matrix 
consisting of a series of FIDs, from which a set of 1D spectra is obtained by Fourier 
transformation with respect to t2• Then, a second Fourier transformation, with respect 
to tJ, yields the final 2D spectrum with two frequency axes, namely F1 and F2• 
2.2.1) COrrelation SpectroscopY (COSY) 
This technique was first proposed by Jeener13 and then published by Aue et al. 14• The 
pulse sequence is shown in figure 1.1 0. 
12 
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The COSY experiment consists of a 90° pulse to transfer the magnetisation into the y 
direction. This is followed by an evolution time, ft. which is arrayed, during which 
the chemical shift and the spin-spin coupling develops. Then, a second 90° pulse is 
applied before acquisition, which transfers the magnetisation between spins that are 
coupled. The time t1 gives the second dimension of the spectrum while the time h 
give the first dimension. 
90ox 90ox 
'H D· t, {l/\ : " : v\}V <» 
Figure 1.10: Pulse sequence for a COSY experiment. 
The COSY experiment generates a 2D spectrum in which the cross-peaks appear if 
spin coupling is present. Thus, this sequence detects coupled pairs of protons. 
2.2.2) Heteronuclear Single Quantum Coherence (HSQC)15 
The sequence, shown in figure 1.11, starts with a transfer from 1 H to 13C, by the 90°-
d2-180° -d2-90° sequence on the proton channel and the 180° -d2-90° sequence on the 
13C cbanneL This is followed by a t1 period, which is arrayed, including a 180° pulse 
on the proton channel. During t1 the 13C chemical shift develops, and the 180° pulse 
on the proton channel is present to refocus the J(C,H) spin coupling that develops in 
the second dimension. The 90°-d2-180° sequence is a transfer from 13C to 1H . The 
parameter d2 is set to 11[4J(C,H)]. 
Figure 1.11: Pulse sequence for a HSQC experiment. 
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The HSQC experiments generates a 20 spectrum in which the peaks show protons 
directly bonded to Be atoms. 
2.2.3) Heteronuclear Multiple Bond Correlation (HMBC)16 
The pulse sequence is shown in figure 1.12. 
The 90°-d2-180°-dz-90° sequence on the proton channel and the 180° pulse on the 
Be channel correspond to a BIRD filter, which allows rotation of the magnetisation 
of the proton attached to 12C into the z direction, but leaves the magnetisation of the 
proton attached to Be unchanged. This allows one to observe only the proton 
attached to Be. The first 90° pulse on the Be channel acts as a low-pass filter to 
suppress the 1-bond correlations. The 90°-d4+d5-t112-180°-t112+d2 sequence on the 
proton channel and the 90°-t1-90° sequence on the Be channel correspond to an 
HMQC experiment, which allows the evolution of the Be chemical shifts, the C,H 
spin coupling, while suppressing the proton chemical shifts and the H,H spin 
coupling. The term d2 is set to 50 ms, d3 is the BIRD delay, which should be 
optimised for minimum FIO, d4 is set to 1/[2J(C,H)] and d5 is equal to dz-d4• 
180\ 
D 
Figure 1.12: Pulse sequence for a HMBC experiment. 
The HMBC experiments generates a 20 spectrum in which the peaks show protons 
bonded to Be atoms. 
3/ Amorphous state 
An amorphous solid may be obtained in four different main ways: vapour 
condensation, precipitation from solution (e.g. spray-drying), supercooling of melt, 
and milling. The supercooling of the melt is simply a rapid cooling of a liquid where 
the liquid goes through a supercooled liquid or rubbery state (i.e. an e_}(~r_e!!l~lY. 
14 
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viscous liquid) before reaching Tg, the glass transition temperature. Below Tg, the 
material is "kinetically frozen" into a metastable glassy state, which is the amorphous 
state17• 
Amorphous compounds are of importance for pharmaceutical companies as they 
have increased solubility rate compared to their crystalline counterparts. Therefore, 
amorphous forms in a formulation could potentially improve the oral bioavailability 
of poorly water-soluble drugs, such as the ones studied here 18•19• However, due to the 
metastable nature of the amorphous form, pharmaceutical companies tend not to 
formulate. amorphous drug substances. A known exception is that of cefuroxime 
axetil; the amorphous form of this compound obtained by spray drying is physically 
and chemically stable without too rigorous storage conditions. In view of this, it is 
clear that it is of paramount importance to understand why some pharmaceutical 
drugs are stable in their amorphous form while others rapidly recrystallise, or require 
strenuous storage conditions, i.e. low temperature and humidity. Pharmaceutical 
companies are also interested in detecting and controlling small amounts of 
unwanted and unintentional amorphous materials which could be formed during the 
processing techniques. 
The amorphous state has been the centre of quite a variety of research, from general 
information20•21 to the differences between the amorphous and crystalline state22-24, 
but more importantly on solubililf5 and molecular motions26• 
It is understood that changes in the molecular mobility of an amorphous drug could 
lead to recrystallisation of the material, e.g. in a formulated product, and this .can 
change drastically the bioavailability of the drug. As a result, much research has been 
carried out in order to improve the stabilisation of the amorphous form of drugs or 
drug-carrier dispersions27•28 • 
It is important to know that one should be careful in the preparation of the dispersion; 
Watanabe et al.29 showed that the presence of silica decreased the recrystallisation 
rate of amorphous indomethacin on both co-grinding and quench-cooling and that the 
co-grinding technique gave slightly better results. However, if the co-grinding was 
incomplete the amorphous form obtained was quite unstable29 • 
_... __ , .~ .. · "'· .. ·_._.,_._. _, ___ ,.....____ -.~ ... ,_ -_ 
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3.11 Plasticiser and antiplasticiser effect 
The plasticiser effect is a lowering of the Tg caused by the presence of water in the 
sample. Andronis et al. 30 showed that indomethacin, a poorly soluble drug, absorbed 
a large quantity of water when in the amorphous form. The presence of water 
increased the molecular mobility of the amorphous sample and thus increased its 
recrystallisation rate. Therefore, it is necessary to add some form of physical 
stabilisation to the amorphous sample to maintain the glassy state and to prevent 
recrystallisation. This is generally achieved by stringent conditions of storage. 
However, this is not really practical in many situations, and some level of residual 
water is difficult to avoid31 • The other option is to stabilise the amorphous sample by 
the addition of an antiplasticiser, a compound with a high Tg, which will generally 
be a polymer. Aso et al.32 showed that by mixing amorphous nifedipine with various 
compounds, the recrystallisation rate could be decreased due to the hygroscopic 
compounds preferentially taking up water. It was also shown by Gupta et al.28 that 
the effect of grinding a sample with Neusilin (amorphous magnesium 
aluminosilicate) improved the amorphisation and also resulted in a more stable 
amorphous drug. 
Bulk polymers such as PVP have been widely used to stabilise amorphous drugs. 
PVP was shown to improve the stability of an amorphous drug even when increasing 
the relative humidity33 • It was also shown to inhibit the crystallisation of lactose for a 
significant period of time34, whilst Forster et al.35 showed that the presence of PVP 
increased the dissolution rate of indomethacin and nifedipine, more so as glass 
solutions than as physical mixtures. 
4/ Indomethacin 
Indomethacin is a nonsteroidal anti-inflammatory drug used in the relief of some 
pain problems, such as arthritis and tendonitis. Indomethacin has three recognised 
anhydrous polymorphs36 generally referred to as the a-, P- and r-forms37 • Imaizumi 
et al.38 refer to the a and 'Y polymorphs as forms I and II respectively. Kistenmacher 
et al.39 determined the crystal structure of the r-form, the stable form under ambient 
conditions37, and its melting point is 158°C37• The crystal structure of the a-form is 
also known40• 
16 
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The crystallinity of indomethacin and the recrystallisation rate of its amorphous form 
has been studied as a function of temperature and also relative humidity using a 
variety of techniques26•30•38•4145• Fukuoka et al.46 showed that amorphous 
indomethacin has an increased dissolution rate compared to the crystalline form and 
also that, when kept intact, amorphous indomethacin was stable for up to 2 years at 
room temperature, but recrystallised rapidly when crushed. The effect of the addition 
of PVP to amorphous indomethacin was also studied47 and it was shown that 
amorphous indomethacin was more stable when in dispersion with PVP than on its 
own or in a physical mixture. 
Yoshioka et al.48 showed that indomethacin could recrystallise rapidly when crushed 
and kept at temperature 30°C below Tg; they show evidence that the rotational 
mobility of indomethacin under these conditions is the reason why the 
recrystallisation occurs. They also showed that the method of preparation of the 
amorphous material was important as it could affect its physicochemical properties. 
Crowley et al.36 studied the effect of a specific method of grinding on the different 
polymorphs of indomethacin and showed that this technique did not necessarily 
produce an amorphous sample. Therefore, one should check the amorphous character 
of a sample after its preparation. 
5/ Nifedipine 
Nifedipine is a calcium channel blocker drug. This compound is used in the 
treatment of hypertension and coronary heart disease. Burger and Koller found that 
nifedipine had three anhydrous polymorphs and labelled them as modifications I, II 
and 11149 but earlier Hirayama et al.50 used the letters A and B rather than I and II. 
The modification I, which is the stable form under ambient conditions, was also 
studied by Caira et al.51 • The structure of this polymorph has been determined52 and 
its melting point is 173°C50• 
Aso et al. studied amorphous nifedipine quite extensively2•32·53-55 . They showed that 
the presence of moisture increased the crystallisation rate and mobility of nifedipine 
and also that nifedipine had a lower crystallisation rate when kept at low 
temperature. However, they observed that amorphous nifedipine showed 
considerable crystallisation within 4 months when kept at 40°C below its Tg. 
Nevertheless, they showed that the presence'"of PVP' increased the stabllity of the 
17 
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amorphous sample, which is due to a decrease in molecular mobility. One of Aso et 
al. articles2 dealt with the study of T1H and T1pH of amorphous nifedipine at a 
magnetic field of 25 MHz over a short range of temperatures (i.e. 5°C to 75°C). 
They showed that the relatively fast recrystallisation observed with amorphous 
nifedipine could be due to the high molecular mobility. 
6/ Carbamazepine 
Carbamazepine is an anticonvulsant. This molecule is used to treat certain types of 
seizures in the treatment of epil~psy. The polymorphism of carbamazepine has been 
widely studied, showing that this drug has four anhydrous polymorphs. These are 
generally labelled as forms I, II, III and IV56, though Roberts et al.57 used the 
symbols a and ~ instead of II and Ill. The crystal structure of form Ill, the stable 
form under ambient conditions, has been determined58•59 and its melting point is 
174°C60• Harris et al.61 did an extensive structural study ofthe different polymorphs 
and pseudo polymorphs of. carbamazepine using SSNMR and computational 
chemistry. 
Amorphous carbamazepine, in comparison to the crystalline form, has been little 
studied. However, it was shown62 that carbamazepine in dispersion with povidone 
was amorphous and that dispersions of carbamazepine in povidone and polyethylene 
glycol showed improved dissolution rate of the drug compared to the crystalline drug 
on its own. 
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11 General information 
The use of different characterisation techniques are likely to involve differences in 
the physical nature of the samples and the way they are handled in terms of the data 
obtained. Therefore, properties, such as rates of crystallisation and Tg itself, may 
depend on the sample preparation used. 
1 .1 I Materials 
Samples of indomethacin (1), nifedipine (II) and carbamazepine (Ill) were provided 
by Sigma Aldrich (UK). Poly(vinylpyrrolidone) (PVP k30, average MW 50,000) 
(IV) was supplied by GlaxoSmithKline (UK). All sample were used without further 
purification. Nifedipine and carbamazepine were stored in the fridge and protected 
from light during storage and they were, as far as it was possible, protected from 
light during sample preparation and experimentation. The chemical stability of the 
compounds was checked by proton NMR of solutions in DMSO-d6 following the 
procedures discussed below for TGA and variable-temperature solid-state NMR 
measurements. The numbering systems used for solid-state forms of compounds I, 
II and III were obtained from the papers by Kistenmacher & Marsh 1, Triggle et a! _2 
and Himes eta!? respectively. 
OH 10-11 I 1-\ /N02 
CH3 18-19 9 12 0 CH b 5 I ~ '\_(! \._j3 " 3 
"6/ ~4---~ \ I II I \ 2-9~3 o I' 4-3 7 
"'--s::?9.__N/ '\ '-5~ \2-CH 
\ /1~15 I ~ I 2' 3 
~0-11 \ H3~-.. -0 6-N 
o \\ /14-cl I H 
12-13 H3~, 
I. Indomethacin II. Nifedipine 
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III. Carbamazepine 
1.2/ Preparation of amorphous. samples 
~n (yo 
IV.PVP 
For the static 1H spectra and relaxation experiments, approximately 500 mg of the 
crystalline drug was melted in an oven in glass tubes I em in length. Nifedipine was 
melted at 180 oc for 5 minutes, indomethacin at 171 oc for 10 minutes and 
carbamazepine at 195 oc for 5 minutes. Then, the sample was put in a pre-cooled 
mortar and liquid nitrogen was added in this mortar after one minute for 
indomethacin and nifedipine, or straight away for carbamazepine. Amorphous 
indomethacin and nifedipine appeared as transparent yellow glasses straight after 
cooling, while amorphous carbamazepine appeared as a transparent amber glass. The 
thermal degradation of the compounds was investigated with thermo gravimetric 
analysis by holding the crystalline samples for an equivalent time, i.e. 5-10 minutes, 
and at the same temperature, i.e. 171 °C, 180 oc or 195 °C, as used during the 
sample preparation process. All samples showed less than 3 % weight loss, 
indicating satisfactory thermal stability. A solution-state NMR spectrum, obtained 
after a TGA experiment, was used to confirm this low level of degradation, ca. I %. 
This approach of preparing the amorphous samples directly in the glass tubes was 
chosen to prevent the need for grinding solidified melts and to reduce the amount of 
water adsorbed by the sample following preparation. However, for the 13C 
experiments it was decided to stop quench cooling the melt straight into the rotor in 
order to avoid stress on the rotor. Instead, the sample was melted, quench-cooled and 
ground in a beaker. In order to avoid recrystallisation, the grinding was done with the 
beaker placed in a bath of liquid nitrogen. The 13C SSNMR spectra of the samples 
treated this way were the same as those obtained when quench-cooling in the rotor. 
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21 Nuclear Magnetic Resonance (NMR) 
2.11 Solid-State NMR (SSNMR) 
2.1.1) Spectrometers and probes 
Two different spectrometers have been used primarily. One is a Varian InfinityPlus 
500, used with a HX 7.5 mm MAS probe or a HX 2.5 mm MAS probe. This 
spectrometer operates at a proton frequency of 499.75 MHz and at a Be frequency of 
125.68 MHz. The other spectrometer was a Chemagnetics CMX 200, used with a 
7.5 mm MAS probe or a static probe fitted with a 10 mm o.d. coil. This spectrometer 
operates at a proton frequency of 200.13 MHz and a 13C frequency of 50.32 MHz. 
For both spectrometers, the two channels were used for the MAS probes. One 
channel was used for observing Be signals and the other allowed cross-polarisation 
from and decoupling of protons, as well as direct 1H observations. The static probe 
used only one channel for direct 1H observations. 
Some of the relaxation data have been previously acquired by D.C. Apperley on a 
Varian UnityPlus 300, which operates at a proton frequency of299.946 MHz. 
Another spectrometer has been used specifically for the study of quadrupolar effect 
for indomethacin. It was a Varian InfinityPlus 800, used with a 5 mm MAS probe, 
which was situated at the Rutherford-Appleton laboratory, Oxfordshire. This 
spectrometer operated at a proton frequency of 699.72 MHz at first, then at 799.76 
MHz once the magnet reached full field. The spectra at 700 MHz and 800 MHz were 
obtained by P.Y. Ghi. 
2.1.2) Experimental setup 
2.1.2.1) Setting the magic-angle 
Setting the magic-angle properly is an important task as, if the sample is not at the 
magic-angle, the CSA and heteronuclear dipole interactions will not be fully 
averaged. Therefore, they will complicate the spectra. The magic-angle should be set 
every 1 or 2 weeks. It is also good practice to set the angle again after a VT 
experiment, as the change of temperature can affect the angle. 
I~ ~r~er to set t~is an~~e.PTOP~!ly, ,a" sail!:~)~ .<J.fp,c>!~,~~J.ll'!!"~r9Q1J9~J~.,sp_tAr!. and ~ 79Br 
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spectrum is acquired with 32 to 64 acquisitions and a short pulse delay, i.e. 0.1 s. The 
number of acquisitions is chosen with the aim of obtaining a good signal to noise 
ratio to help with a fine adjustment. The next step is to move the transmitter to have 
the centre band on resonance. Then a FID is acquired to check the train of rotational 
echoes, which should be up to 10 ms in duration if the angle is set properly. If this is 
not the case, the angle needs adjustment until a satisfactory echo train is observed. 
2.1.2.2) Setting the 90° pulse 
The duration of the 90° pulse depends on the probe; in our case, it was mainly set to 
5 JlS, and is determined using adamantane. The sa_mple is either spun at 2-3 kHz or 
static. The experiment is carried out by repetitively/continuously acquiring proton 
spectra whilst manually increasing or decreasing the amplifier power such that a null 
signal may be observed at twice the chosen 90° pulse duration for proton. At the 
point when a null signal is observed, it is assumed that the proton magnetisation has 
precessed through 180° and thus there is no component along the axis of observation. 
Then an array is done in order to confirm this and the 90° pulse value is the 
difference between 360° and 180° divided by two. This technique to get the value of 
the 90° pulse was used, as it is the technique employed by the manufacturer when 
giving the probe specifications. The same procedure is done for the carbon signal of 
adamantane and another 90° pulse value, normally the same as for protons, is 
determined. 
2.1.2.3) Setting the Hartmann-Hahn condition (CP experiments only) 
The previous section sets the Hartmann-Hahn condition. Nevertheless, we want this 
to be more accurate. Therefore, we change the value of the X CP power whilst 
observing adamantane. This value corresponds to the power used on the X channel 
during the contact time. One just needs to array the value in decreasing steps and 
from this experiment use the X CP value giving the highest intensity spectrum. In 
addition, one can also check that the H CP power, the power used on the proton 
channel during the contact time, is optimal by doing an analogous procedure. 
However, it is expected that the value for the H CP power should be equal to the 
maximum power used during the experiment, i.e. 90° pulse power. 
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2.1.2.4) Setting the recycle delay and the contact time 
The recycle delay is the time between the end of the acquisition of one FID and the 
next sequence of radio frequency excitation. It is important to choose this time 
carefully as it determines the strength of signal that will be detected. It should not be 
too short, as this can result in a loss of the signal due to saturation, and could degrade 
the probe and/or the sample by heating effects. On the other hand, too long a recycle 
delay will result in a waste of spectrometer time. 
The recycle delay is sample dependent, as it will directly derive from T 1 H for a CP 
experiment or T1x for a DP experiment on nucleus X. It should be about five times 
T 1 for the best signal intensity, or -1.2 x T 1 for the best signal to noise ratio (SIN). 
However, it is not necessary to measure T1 to determine the best recycle delay. It is 
possible to do an array on the recycle delay which will enable the experimentalist to 
determine the best time. This best time will depend on whether a quantitative 
experiment or a good SIN is wanted. 
The contact time for a CP experiment has to be determined in order to have the best 
signal transferred between the abundant and the dilute spins. This is done by doing 
an array on the contact time. The time for which the signal has the strongest intensity 
will be the best contact time. It is important to note that the signal intensity varies 
across the spectrum, e.g. a quaternary carbon will usually need a longer contact time. 
This time should be long enough to allow maximum magnetisation to be transferred 
from one spin to another. It also should be short enough in order to avoid the 
magnetisation leaking to the lattice. This consideration depends on T 1 PH. In effect, 
the data from the contact time array can be fitted to equation 2.1, which is the 
equation for the intensity of the signal. 
y =amp •[ exp( ;.: ) -exp( ;c:)] Equation 2.1 
where "amp" represents the intrinsic amplitude of the peak, T 1PH is the spin-lattice 
relaxation time in the rotating frame of resonance, T cP is the time constant of the CP 
experiment and t is the contact time which is the arrayed parameter. 
2.1.2.5) Referencing 
In order to ensure comparability of resqlts,, it is necessary to reference tl:re chemical 
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shifts in the spectra to a recognised standard. In our case, adamantane was used as a 
standard for 13C and PDMSO was used for 1H. The high-frequency 13C peak of 
adamantane has a chemical shift of 38.4 ppm with respect to TMS, and PDMSO has 
a chemical shift of 0.1 ppm with respect to TMS. It is good to note that the 
referencing for proton is only important when a resolved spectrum is obtained. 
2.1.3) Variable Temperature (VT) experiments 
2.1.3.1) VT calibration 
The VT calibration has to be ·done specifically for every probe, and at a specific 
spinning speed, as the speed influences the sample temperature. The aim of this 
calibration is to find the temperature in the rotor and to compare it to the value set by 
the spectrometer operator (this will be referred to as the reading temperature from 
now on). This will give a curve that will then be used, when doing a VT experiment, 
to find out the temperature in the rotor knowing the one recorded on the 
spectrometer. 
The calibration is done in two steps. The first will be to find an absolute temperature. 
In order to achieve this, methanol is used and from the difference, in Hz, between the 
two proton peaks, a temperature is found, which will be the absolute temperature. 
This is generally done with a reading temperature of about 20°C to 25°C. 
The second step is done using lead nitrate (Pb(N03)z). The chemical shift of the 207Pb 
signal is temperature dependent, and therefore will give information on the 
temperature in the rotor. This is done with equation 2.24. The shape of the signal is 
interesting as it gives information on any temperature gradients that are present 
inside the rotor. 
8 = Tx0.753ppm/°C Equation 2.2 
The VT calibration of the static probe used for this study is shown in appendix I and 
the precision of the calibrated temperature is± 1.0°C. 
31 . 
Chapter Two: Experimental 
2.1.3.2) VT method 
The VT equipment was mainly used for the measurement of proton relaxation times. 
VT 13C SSNMR of amorphous materials was also performed. The method used to do 
the VT experiments is as follows: 
1. Insert a dewar of liquid nitrogen in the line. 
2. Change the pipeline in order to use nitrogen gas as cooling/heating gas. 
3. Set the purge and heater gas to the appropriate flow (ca. 90 SCFH for low 
temperature and ca. 110 SCFH for room temperature and above). 
4. Start the experiment at the lowest temperature, in our case ~ 70 °C. 
5. Acquire a T1H saturation-recovery experiment followed by a T1pH spin-lock 
experiment. Then increase the temperature. 
6. When reaching 20 °C, it is good practice to reduce the temperature, down to ca. 
-20 °C, at the control before switching the controller off 
7. Remove the dewar of liquid nitrogen out ofthe line. 
8. Carry on the rest of the experiments until the whole range of temperature is 
complete. 
It is good to note that when the controller is switched off, the temperature inside the 
probe rises quite quickly due to compensation by the probe. This can cause some 
problems with temperature-dependent compounds, such as amorphous nifedipine. It 
is for this reason that the temperature is lowered before switching off the controller. 
2.1.4) Carbon-13 SSNMR 
Carbon-13 spectra were recorded with cross polarisation, magic-angle spinning and 
high-power proton decoupling using the Chemagnetics 200 spectrometer, operating 
at 50.32 MHz. A probe using 7.5 mm diameter rotors made of zirconia was 
employed. For all experiments, PTFE end caps were used. Typical operating 
conditions utilised a contact time of 3-5 ms, a recycle delay of 12-60 s, 512 transients 
and a spin rate of 4.5-5.5 kHz. For assignment purposes, spectra of non-protonated 
and protonated carbons were separately obtained using a dipolar dephasing pulse 
sequence5• Carbon-13 variable-temperature measurements were performed for 
amorphous indomethacin and nifedipine, from 22°C to 80°C for the former and from 
-40°C to 55°C for the latter. An analogous experiment was performed on crystalline 
indomethacin at -80 °C, 
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2.1.5) Proton SSNMR 
The InfinityPlus 500 was used to do 1H high-speed experiments on all three 
crystalline compounds and 13C experiments on crystalline indomethacin. For the 
high-speed experiments, a HX 2.5 mm probe and a spinning speed of ca. 25 kHz 
were used. For the 13C experiments, a HXY 7.5 mm probe and a spinning speed of 
ca. 5 kHz were used. 
Proton wideline NMR spectra and relaxation times (T1 and T1p) for static samples 
were measured at 200.13 MHz using a Chemagnetics CMX 200 spectrometer and at 
299.95 MHz using a Varian Unity Plus 300 spectrometer. Values ofT1 were derived 
from a saturation-recovery experiment with twelve delay times for each 
measurement. This experiment involves applying a series of one hundred 90° radio 
frequency pulses (duration 5 ~ for the work at 200 MHz but 1.8 ~ at 300 MHz) 
separated by a time of 100 JlS, equalising the populations of the spin states which 
subsequently relax to their equilibrium situation. A series of delay times is then used 
prior to a 90° read pulse in order to map the relaxation rate6• This approach is 
particularly useful for systems with long T1 values because a conventional inversion-
recovery experiment may take a prohibitively long time. In the saturation-recovery 
case, only a short recycle delay (0.1 s) is required after data acquisition before a new 
series of saturation pulses can be applied. T1p measurements were performed by 
varying a spin-lock time (twelve different values) following a 90° radio frequency 
pulse (duration as for the T1 measurements). The relaxation delay used in this case 
was equal to four times the measured T1• For spin-locking, a radio frequency field 
equivalent to 50 kHz (200 MHz) or 70 kHz (300 MHz) was used. 
Each decay curve (for both T1 and T1p measurements) was fitted to a single or double 
exponential using the Origin 6.1 software. When a double exponential was used the 
value for T1H or T1pH was obtained using the population weighted rate average. A 
series of such measurements was performed over a wide temperature range for all 
samples, including the drug/PVP co-melts but excluding PVP itself. The fitting to a 
double exponential was only done for high temperatures and principally for the T1p 
measurements. When a double exponential was needed one of the exponential 
represented at least 90% of the total, i.e. the other one did not influence much the 
stated results. 
In order to obtain the decay curves, three methods were inve!)tigated: the peak height, 
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the peak integral and the first point of the FlO. It was found that the most robust and 
easily reproducible was to use the first point of the FlO. The reproducibility and 
easiness of use was managed by writing a simple macro. 
As sample robustness is of particular interest, accurate time recording was performed 
beginning at the time of sample preparation for each set of measurements. The 
relaxation measurements for the three drugs were performed for two separately 
prepared quench-cooled melts. 
The protocol used for proton NMR measurements was generally as follows: 
1. The relevant sample was melted in an oven in a glass tube (10 mm o.d.) at 
171 oc for 10 minutes, 180 oc for 10 minutes and 195 oc for 5 minutes, for 
indomethacin, nifedipine and carbamazepine respectively. It was kept in the tube 
throughout the experiments. 
2. On removal from the oven, the tube was placed in a pre-chill~d mortar and, after 
about 1 minute for indomethacin and nifedipine and straight away for 
carbamazepine, liquid nitrogen was poured over it, producing a clear yellow or 
amber glass. In the case of the PVP/drug mixtures, the sample was poured in a 
pre-chilled mortar and liquid nitrogen was poured directly over it, then crushed 
under liquid nitrogen and put into a tube. 
3. The tube went straight into the spectrometer and was cooled to -70°C (as set 
using the software). Calibration shows that the actual sample temperatures are 
within 2 oc of those set. 
4. The first NMR measurements were started half an hour after the sample went into 
the oven. 
5. A Tt measurement was followed by a Ttp experiment, each with 12 delay times. 
6. Each decay curve was fitted to a single exponential. 
7. The temperature was then increased incrementally. The time allowed for 
equilibration at the new temperature was typically between 10 and 20 minutes, 
after which a new set of measurements was made. 
The only difference for the co-melts was that PVP Was dried at low pressure in an 
oven for a minimum of three hours. Then the sample of PVP was weighed and a 
similar mass of one of the drugs was added. This was followed by the above 
protocol. 
The amorphous samples used for the 13C experiments were prepared by melting the 
sample in a beaker for 10 rriiiu1tes at the appropriate temperature. Then the sample 
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was poured and ground in liquid nitrogen. The preparation of an amorphous sample 
was checked using XRPD. 
2.2/ Solution-state NMR 
Solution-state NMR data were obtained for reference purposes. Spectra for 
indomethacin (in deuterated dimethylsulfoxide) were obtained at a 100.58 MHz for 
13C and at 399.97 MHz for 1H, using a Varian Mercury 400 spectrometer at ambient 
probe temperature. Spectra for nifedipine and carbamazepine (in deuterated 
dimethylsulfoxide and in deuterated chloroform, respectively) were obtained at 
125.70 MHz for 13C and at 499.92 MHz for 1H, using a Varian !nova 500 
spectrometer at ambient probe temperature. All spectra were referenced to the 
solvent signal. For each compound, the full assignments were made using 1H, 13C, 
COSY, HSQC and HMBC experiments. Standard conditions for the COSY 
experiments are 1024 or 2048 data points with 256 increments in F 1 and 1 transient 
in F2 . For the HSQC experiments, these conditions are 1024 or 2048 data points with 
2 x 256 increments in F 1 and 8 transients in F2• For the HMBC experiments, these 
conditions are 1024 or 2048 data points with 400 increments in F 1 and 8 transients in 
F2. 
The solution-state indomethacin and nifedipine 13C chemical shifts and assignments 
are consistent with the work of O'Brien et al. 7 and that of Ali8 respectively, except 
that in the former case the assignments for C-2 and C-4 have been exchanged. The 
solution-state carbamazepine carbon chemical shifts and assignments were not found 
in the literature for comparison, whilst the proton chemical shifts and assignments 
are consistent with the work of Aboul-Enein & Al-Badr9 with increased 
understanding ofthe aromatic region. 
Solution-state NMR was also used to check the stability upon heating of all three 
compounds, as well as their stability after VT experiments. These spectra (in 
deuterated dimethylsulfoxide for indomethacin and nifedipine and in deuterated 
chloroform for carbamazepine) were obtained at 400.13 MHz for 1H and at 
100.61 MHz for 13C, using a Bruker Avance 400 spectrometer at ambient probe 
temperature. All spectra were referenced to the solvent signal. 
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3/ X-Ray Powder Diffraction (XRPD) 
XRPD was used to study the crystalline fomr, confirm that quench-cooling of the 
drugs resulted in the production of amorphous products and for VT investigation. 
All samples were analysed with a Philips X'Pert MPD powder diffractometer (count 
time l second, step size 0.04 °28, Ni-filtered Cu-ka radiation, 45 kV, 50 rnA, sample 
size: approx. 300 mg) 
In the case of the crystalline form, a recessed silicon wafer holder front filled was 
used. In the case of the amorphous form, the samples were melted in an X-ray 
sample holder, TTK front fill holder, on a hot plate and then immediately immersed 
in liquid nitrogen. The powder diffractometer was fitted with an Anton-Parr TTK 
variable temperature camera for the VT experiments. The timescale of the VT 
experiment was similar to the timescale used for the VT SSNMR experiments as far 
as this was possible. 
4/ Differential Scanning Calorimetry (DSC) 
DSC was used to measure the Tg, to measure the melting point of the studied 
samples, to determine the crystalline form of the original samples and to check the 
feasibility of producing an amorphous material by melting and quench cooling it. 
Amorphous samples were prepared by melting the pure drug in lightly crimped 
aluminium pans (open-pan), using a TA Instruments 2920 DSC (Surrey, UK) at a 
heating rate of 10 K min-1 (nitrogen purge: 20 ml min-1). The sample size was about 
5 mg. Temperature and enthalpy calibrations were performed using indium. Quench-
cooling of the samples was performed by placing a liquid nitrogen Dewar over the 
DSC cell. To determine Tg (onset value) the samples were then reheated in the DSC 
using the same conditions, interpretation of the data was done using Universal 
Analysis (TA instruments, Surrey, UK). 
For amorphous nifedipine, a different experiment was carried out using a 
Perkin Elmer Pyris-1 apparatus using a water cooling system and non-hermetically 
sealed aluminium pans. A typical sample weight of 2 to 5 mg was used. In this case, 
the DSC was used in order to gain information on the recrystall isation process. 
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51 Thermo Gravimetric Analysis (TGA) 
TGA was used to determine the stability of the compounds by holding them 10 oc 
above the melting point for up to 10 min and measuring the weight loss. The samples 
were placed in open aluminium pans. The experiments were carried out using a T A 
instruments, Hi-Res. TGA 2950 Thermogravimetric Analyser, with a N2 purge gas 
flowing at 100 ml/min. Typically, samples were about 20 mg. 
61 Microscopy techniques 
Two different microscopy techniques were used: 
- A polarised light microscope was used to determine if a sample was crystalline or 
amorphous. The instrument employed was a Zeiss polarised light microscope 
fitted with JVC digital video camera using Image Pro-plus software to capture 
the image. Powder samples were dispersed on a glass microscope slide using 
mineral oil. 
- A hot-stage microscope was used to investigate the recrystallisation of 
amorphous samples upon heating. A Nikon polarised light microscope was used 
in combination with a Linkam LTS 350 hot-stage fitted with video image 
capture. 
7 I Fourier-Transform Infra-Red (FTIR) spectroscopy 
Samples were analysed by infra-red spectroscopy using an Attenuated Total 
Reflectance (ATR) accessory fitted with a germanium crystal on an Avatar FTIR 
model 360 instrument. Spectra (64 scans at 4 cm-1 resolution) were recorded over the 
4000-700 cm-1 range and analysis was performed using Omnic ESP software. 
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Chapter Three: Crystalline Materials 
11 Materials 
This chapter will deal with the data acquired and the results obtained whilst dealing 
with the crystalline fonns of the three studied drugs. It will detail to what extent the 
different techniques of analysis were used, and demonstrate how the techniques were 
utilised in order to help in the progression of this research. 
Note that for the DSC traces there are two values around each of the peaks, the 
highest values correspond to the temperature at the maximum of the peak, while the 
lowest temperature corresponds to the onset temperature. The onset temperature is 
used when confirming the melting point. 
1 .1/ Indomethacin 
The crystalline fonn studied was the y-fonn, as detennined by XRPD (figure 3.1) 
and DSC (figure 3.2). The results obtained are in agreement with the work of 
Kaneniwa et al. 1• The FTIR of crystalline indomethacin is shown for reference in 
appendix 2. 
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Figure 3.1: XRPD of the y•form of crystalline indomethacin. 
39 
Chapter Three: Crystalline Materials 
5,---------------------------------------.r-------, 
4 
Oi ~3 
~ 
u:: 
iii 
Q) 
I 2 
/-----------------···-··----··· 
160.00'C I 106.8J/~ 
I . . 
162.50'C 
0+-~--~~--~--~~--~~--~~--~~--~----~~ 
0 50 100 150 200 
Exo Down Temperature (°C) 
Figure 3.2: DSC of they-form of crystalline indomethacin showing T m = 160°C. 
The melting point (T m) of the y-form of indomethacin is 160°C 1• The DSC (figure 
3.2) was used to show that the studied form was they-form. 
The solid-state phase relationship of this compound is shown in figure 3.3. This 
confirms that the crystalline form of indomethacin at room temperature is the same 
one as observed by XRPD (figure 3.1). 
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Figure 3.3: Phase relationship of indomethacin 1. 
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The conformation of the asymmetric unit of the y-form of indomethacin is shown in 
figure 3 .4 while figure 3. 5 shows a unit cell. 
Figure 3.4: Conformation of the asymmetric unit of the y-form of indomethacin. 
This crystal has one molecule per asymmetric unit and two molecules per unit celf. 
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Figure 3.5: Unit cell ofthe y-form of indomethacin. 
1.2/ Nifedipine 
The commercial sample provided is the polymorph modification I. This is shown by 
comparing the DSC (figure 3.6) and FTIR (figure 3.7), obtained experimentally, with 
the work of Burger and Koller3. The XRPD of crystalline nifedipine is shown for 
reference in appendix 3. 
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Figure 3.6: DSC of crystalline nifedipine showing T m = 173°C. 
200 
The melting point (T m) of the modification I of nifedipine is 171 °C4• This was 
confirmed using DSC (figure 3.6). 
The FTIR bands at 1689, 1649, 1619, 1192 and 74.6 cm·1 are characteristic of the 
modification e. 
94 i 
93 j 
i 
92 .f 
I 
91 1 
i 
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Figure 3.7: FTIR of crystalline nifedipine. 
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The conformation ofthe asymmetric unit ofthe modification I ofnifedipine is shown 
in figure 3.8 while figure 3.9 shows its unit cell . 
Figure 3.8: Conformation ofthe asymmetric unit ofthe modification I ofnifedipine. 
This crystal has one molecule per asymmetric unit and four molecules per unit cell5 . 
\ 
Figure 3.9: Unit cell of modification I of nifedipine. 
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1.3/ Carbamazepine 
The commercial sample provided is the polymorph modification III as shown by 
comparing the work of Krahn and Mielck6 with the DSC (figure 3.10) and XRPD 
(figure 3.11) obtained for this compound. The FTIR of crystalline carbamazepine is 
shown for reference in appendix 4. 
The melting point (Tm) of the form III of carbamazepine is 174°C6• This was 
confir;,med using DSC (figure 3.10). The DSC shows an endotherm at 175°C 
followed by an exotherm at 177°C corresponding to the melting of form III and the 
crystallisation of form I respectively. The endotherm at l92°C corresponds to the 
melting of form I. 
o; 
~ 
~ 
u:: 
111 
Q) 
I 
6.------------------------------------------------, 
4 
2-
0 
192.7s•c 
176.4o·c 
----······· ~ L __~t- 191.ao·c mz~;; 1068J/g 
-2-1--~~~--.-~~~--.-~~~---,,--~~~---,,--~~~---1 
0 50 100 150 200 250 
Exo Down Temperature ("C) 
Figure 3.10: DSC ofcarbamazepine showing Tmm = 175°C and Tm 1 = l92°C. 
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Figure 3.11: XRPD of the form III of crystalline carbamazepine. 
The work of Grzesiak et al.7 shows that the symmetry of the unit cell of modification 
Ill of carbamazepine, as referenced by Krahn and Mielck6, is P-monoclinic. This was 
confirmed by comparing the work of Harris et al. 8, figure 3.12, with the 13C SSNMR 
spectrum of carbamazepine obtained at 125 MHz, 13C frequency (figure 3.13). 
triclinic 
tri2:onal 
170 160 150 140 130 12 0 110 
Be I ppm 
Figure 3.12: 13C spectra of the four anhydrous forms of carbamazepine obtained at 
125 MHz, 13C frequency. The symmetry ofthe unit cell is specified for each spectra. 
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170 160 150 140 
li/ppm 
130 120 110 
Figure 3.13: 13C SSNMR spectrum of carbamazepine obtained at 125 MHz, 13C 
frequency, showing only the high-frequency part of the spectrum. 
The solid-state phase relationship of this compound is shown in figure 3.14. This 
confirms that the crystalline form of carbamazepine at room temperature is the same 
one as observed by XRPD. 
Carbamazepine 
(commercial) -
Heating at 150°C 
for 3 hours 
Dissolved in ethanol at 80°C. 
Solution slowly cooled to r.t., 
then further cooled to 5 oc for 
5 hours 
Slow evaporation of ethanol 
solution (16.5 mg/ml) at r.t. 
Slow evaporation of methanol 
solution (16.5 mg/ml) at r.t. in 
presence of hydroxypropyl 
cellulose 
Modification I (stable) 
m.p.I89-193°C 
Modification II 
(metastable) 
Transformation 
at 135 - 170 oc 
Modification III 
(metastable) 
m.p. 162- 175 oc 
Modification IV 
(metastable) 
m.p. 178-187°C 
Figure 3.14: Phase relationship of carbamazepine7. 
Heating to 160°C 
for I 0 minutes 
Heating to 182°C 
at 10°C/min 
Heating to 187°C 
for 5 minutes 
The conformation of the asymmetric unit of the modification III of carbamazepine is 
shown in figure 3.15. The unit cell of this polymorph is shown in figure 3.16. 
47 
Chapter Three: Crystalline Mater\als 
Figure 3.15: Conformation of the asymmetric unit of the modification ill of 
carbamazepine. This crystal has one molecule per asymmetric unit and four 
molecules per unit ce116. 
Figure 3.16: Unit cell of modification III of carbamazepine. 
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2/ Results 
2.11 Solution-state NMR 
The second-order effect was investigated for the proton spectra using equation 3.1 9• 
vA -v8 = [(v1 -v4 Xv2 -v3 )]112 Equation 3.1 
where, v A represents the true chemical shift of spin A, v8 represents the true chemical 
shift of spin B and v~, v2, v3 and v4 are the four lines of the AB system from high 
frequency to low frequency. This is shown in figure 3.17: 
lilt 
l l 
VA VB 
Figure 3.17: Representation of the second order effect on an AB spin system. 
However, the deviations from first-order are so negligible in all three cases, 
ca. 0.2 Hz, that the results given in table 3.1, table 3.4 and table 3.5 show the centres 
of the doublets rather than the corrected value. 
2 .1.1) Indomethacin 
The proton and carbon spectra are shown in figure 3.18 and figure 3.19 respectively. 
The assignments of these spectra are shown in table 3 .1. The numbering is the same 
as that shown in chapter Two. 
In order to do the assignment of the 13C and 1 H spectra, the following procedure was 
used. First, the proton spectrum was assigned using tables10, which allowed the 
assignment of the methyl and aromatic protons. Then, the COSY spectrum was used 
to assign the protons of the aromatic ring with the methoxy group attached to it, as 
shown in figure 3.20. Then, the carbon spectrum was assigned using tables10 and the 
HSQC spectrum; this is illustrated in figure 3.21 and figure 3.22. Finally, the carbon 
spectrum was fully assigned using the HMBC spectrum, as shown in figure 3.23. 
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DMSO 
\ 
7 .05 6.85 6.65 
9 8 7 6 5 4 3 2 0 
ppm 
Figure 3.18: Indomethacin proton spectrum, in d6-DMSO. The insets show the 
expansion of the aromatic protons. For a more detailed look at the 7.6-7.7 ppm 
region, see Table 3.3 and its preceding text. 
200 180 160 140 120 100 
ppm 
80 
DMSO+-
60 
Figure 3.19: Indomethacin carbon spectrum, in d6-DMSO. 
40 20 0 
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Figure 3.20: COSY spectrum of indomethacin, in d6-DMSO, showing the 
high-frequency part. 
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Figure 3.21: HSQC spectrum of indomethacin, in d6-DMSO, showing the 
low-frequency part. 
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Figure 3.22: HSQC spectrum of indomethacin, in d6-DMSO, showing the 
high-frequency part. 
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Figure 3.23: HMBC spectrum of indomethacin, in d6-DMSO. Fl : high-frequency 
only. 
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The broad singlet observed for indomethacin at 3.4 ppm is due to the acidic proton, 
but one would expect such a proton to show at around 10 ppm. However, the sample 
was prepared in DMSO and proton exchange can occur between the acidic proton 
and the protons of the residual water. Furthermore, if the amount of water present in 
the NMR tube, mainly associated with the solvent, is far higher than the amount of 
the acidic proton, then this proton will show a signal at a position near that for the 
water in DMSO. 
'H uc 
Chemical shift I Atom Chemical Atom 
Multiplicity ppm number Multiplicity shift I ppm number 
singlet 2.20 17 Singlet 13.3 17 
Water in 
broad singlet 3.38 DMSOa Singlet 29.6 18 
singlet 3.64 18 Singlet 55.4 20 
singlet 3.74 20 Singlet 101.7 5 
doublet of 
doublets 6.69 7 Singlet 111.4 7 
doublet 6.90 8 Singlet 113.5 3 
doublet 7.02 5 Singlet 114.6 8 
second order 12, 13, 
multiplet 7.61-7.67 15, 16 Singlet 129.1 13, 15 
Singlet 130.2 9 
Singlet 130.8 4 
Singlet 131.2 12, 16 
J coupling 0 Singlet 134.2 II 
Chemical shift 
/ppm J /Hz Singlet 135.2 2 
6.69 hs = 8.8 Singlet 137.7 14 
6.69 hs = 2.5 Singlet 155.6 6 
6.90 ls-7 = 8.8 Singlet 167.9 10 
7.02 Js-7 = 2.5 Singlet 172.2 19 
• Note that the peak at 3.38 ppm mcludes the acidic proton, see text. 
b Note that the value of 15-8 is too small and as such it cannot be resolved. The J couplings for the 
second order multiplet are shown in table 3.3. 
Table 3.1: 1H and 13C chemical shifts with assignment and JH-H of indomethacin. 
The Chemical Database Service (CDS) was checked in order to confirm the 
assignments. This showed a good agreement with the experimental, although some of 
the 1H and/or 13C assignments differed from "predicted" assignments. This was 
caused by the way the database looks for atoms with similar environments and for 
53 
Chapter Three: Crystalline Materials 
some cases the number of matches is low. Therefore, the assignment was considered 
as inaccurate and the experimental assignment was used, see table 3.2 for the 
comparison on indomethacin. The comparisons for nifedipine and carbamazepine are 
shown in appendices 8 and 12 respectively. The difference between the database and 
the experimental values could also be due to the use of a different solvent. 
1 H database 11 'H experimental 
Atom Chemical shift I Number of 
number ppm matches Atom number Chemical shift I ppm 
17 2.45 1 17 2.19 
18 3.68 4 OH 3.38 
20 3.81 371 18 3.64 
7 6.61 1 20 3.74 
8 6.89 1 7 6.69 
5 7.17 1 8 6.90 
13, 15 7.45 8 5 7.02 
12, 16 7.56 2 12, 13, 15, 16 7.61-7.67 
OH 12.05 2 
uc database'' '_jc e~gerimental 
Atom Chemical shift I Number of 
number ppm matches Atom number Chemical shift I ppm 
17 18.9 3 17 13.3 
18 39.3 I 18 29.6 
20 55.2 13 20 55.4 
5 100.3 3 5 101.7 
3 103.2 2 7 111.4 
7 111.4 2 3 113.5 
8 124.2 2 8 114.6 
4 127.6 33 13, 15 129.1 
12, 16 128.2 10 9 130.2 
13, 15 128.7 10 4 130.8 
11 134;2 122 12, 16 131.2 
14 137.6 37 11 134.2 
2 135.2 
9 145.5 2 14 137.7 
6 153.6 3 6 155.6 
10 168.2 231 10 167.9 
19 175.0 1 19 172.2 
The author whtch to acknowledge the use of the EPSRC's Chemtcal Database Servtce (CDS) at 
Dares bury. 
Table 3.2: Comparison between the experimental results and the database 
predictions for the assignment of 1 H and 13C in the case of indomethacin. 
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Another problem occurs in the 1 H spectrum of indomethacin. The protons from the 
phenylene ring (attached to the chlorine) show a second-order multiplet centred at 
around 7.64 ppm that is difficult to interpret. In order to get more information, an 
experiment was done with indomethacin in d6-acetone using the Varian Inova 500 
spectrometer. This experiment shows an [ABh pattern, see figure 3.24 (bottom). 
Abraham12 gives a method to interpret such second-order patterns, which was used to 
gain a set of data for the different 1 couplings involved. These values were obtained 
on the assumptions that 112-16 and 1 13_15 are equal, and that 1 12_15 and 113-16 are 
negligible. Then this set of 1 coupling values was used to do a simulation, which was 
slightly different from the experimental. However, when looking at the simulation 
with a reduced linewidth, it was possible to see that 1 12_16 and 1 13_15 are slightly 
different. The results shown in table 3.3 give the final data used to do the simulation, 
and the comparison between simulation and experiment is shown in figure 3.24. 
112-16= 2.4 Hz 
112-13 = 8.5 Hz 
112-15 = 0 Hz 
116-13 = 0 Hz 
116-15 = 8.5 Hz 
113-15 =2Hz 
812 = 816 = 7.76 ppm 
813 = 815 = 7.66 ppm 
Table 3.3: This table shows the 1 coupling and the assignment of the protons 
attached to the para-substitued benzene ring. 
It should be noted that the values of 1 12_15 and 1 13_16 used for the simulation were set 
to 0 Hz. This was because the effect of these couplings is too small to be resolved 
within the experimental linewidths, in this case about 1 Hz. However, for the 
experimental, these values should be mentioned as less than the linewidths. 
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1.18 1.16 1.14 1.12 1.10 1.68 I. 66 7.64 1.62 1. 60 ppm 
Figure 3.24: Comparison between experimental (bottom) and simulation (top) 
spectra of indomethacin in deuterated acetone, showing only the region of the para-
substitued benzene protons. 
2.1.2) Nifedipine 
The 1H and 13C spectra of nifedipine are shown in figure 3.25 and figure 3.26 
respectively. The assignment was carried out in the same manner as for indomethacin 
and the numbering is the same as that used in chapter Two. The COSY, HSQC and 
HMBC spectra are shown in appendices 5, 6 and 7 respectively. The assignments and 
J coupling are shown in table 3.4. 
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Figure 3.25: Nifedipine proton spectrum, in dt;-DMSO. The inset shows an 
expansion of the aromatic protons. 
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Figure 3.26: Nifedipine carbon spectrum, in d6-DMSO. 
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! 
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IH uc 
Chemical shift I Atom Chemical· Atom 
Multiplicity ppm number Multiplicity shift I ppm number 
singlet 2.25 2', 6' singlet 18.9 2', 6' 
singlet 3.45 3", 5" singlet 34.6 4 
singlet 5.49 4 singlet 51.3 3", 5" 
triplet 7.35 10 singlet 102.0 3, 5 
doublet 7.46 8 singlet 124.3 11 
triQ_let 7.59 9 singlet 128.1 10 
doublet 7.70 11 singlet 131.3 8 
singlet 9.03 NH singlet 133.9 9 
singlet 142.7 7 
1 coupling singlet 147.2 2,6 
Chemical shift 
/ppm 1 /Hz singlet 147.9 12 
7.35 110-11 = 110-9 = 7.5 singlet 167.6 3', 5' 
7.46 1s-9 = 7.5 
7.59 19-10 = 19-8 = 7.5 
7.70 111-10 = 7.5 
Table 3.4: 1H and 13C chemical shifts with assignment and 1H-H ofnifedipine. 
2.1.3) Carbamazepine 
The 1H and 13C spectra of carbamazepine are shown in figure 3.27 and figure 3.28 
respectively. The assignment was carried out in the same manner as for indomethacin 
and the numbering is the same as that used in chapter Two. The COSY, HSQC and 
HMBC spectra are shown in appendices 9, 10 and 11 respectively. The assignments 
and 1 coupling are shown in table 3.5. 
The broad singlet observed at 4.8 ppm is probably due to proton exchange. This 
could also have been caused by rapid internal motion about the N-CO(NHz) bond. 
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7.5 7.45 7.4 7.35 7.3 7.25 
10 9 8 7 6 5 4 3 
ppm 
Figure 3.27: Carbamazepine proton spectrum, in CDCh. The inset shows an 
expansion of the aromatic protons. 
CDCI3 
/ 
190 170 150 130 110 90 70 50 30 10 
ppm 
Figure 3.28: Carbamazepine carbon spectrum, in CDCh. 
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IH '"'C 
Chemical shift I Atom Chemical Atom 
Multiplicity ppm number Multiplicity shift I ppm number 
broad singlet 4.82 NH2 singlet 128.0 4, 11 
singlet 6.94 7, 8 singlet 129.0 2, 13 
doublet of 
triQ_lets 7.33 4, 11 singlet 129.7 3, 12 
doublet of 
doublets 7.37 5, 10 singlet 129.8 5, 10 
doublet of broad 
triplets 7.43 3, 12 singlet 130.7 7, 8 
doublet of 
doublets 7.47 2, 13 singlet 135.2 6,9 
singlet 140.2 1, 14 
1 coupling singlet 157.5 15 
Chemical shift 
/ppm 1 /Hz 
7.33 h2 = 111-IJ = 0.75 
7.33 h3 = 111-12 = 7.5 
7.33 hs = 1u-lo = 7.5 
7.37 1s-3 = 1to-12 = 1.5 
7.37 1s-4 = 1to-ll = 7.5 
7.43 hs = 112-1o = 1.5 
7.43 13-4 = 112-11 = 7.5 
7.43 h2 = 112-13 = 7.5 
7.47 h3 = 113-12 = 7.5 
7.47 1z-4 = 1n-ll = 0.75 
Table 3.5: 1H and 13C chemical shifts with assignment and 1H-H of carbamazepine. 
2.2/ SSNMR 
2.2.1) Indomethacin 
2.2.1.1) 1H spectrum 
A fast MAS 1H spectrum was acquired using the HX 2.5 mm probe on the 500 MHz 
spectrometer, see figure 3.29. The peak at 12.6 ppm is due to the acidic proton and 
oxygen forming a hydrogen bond; the peak at 6.2 ppm is due to the aromatic protons 
and the peak at 2.3 ppm is due to the remaining protons. 
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20 15 10 5 
8/ppm 
0 -5 -10 
Figure 3.29: 1H spectrum of crystalline indomethacin, acquired at 500 MHz 1H 
frequency, spinning at 27 kHz. 
2.2.1.2) 13C spectra 
The 13C SSNMR spectrum of crystalline indomethacin was acquired using CPMAS 
and NQS (figure 3.30) techniques. The assignments, shown in table 3.6, were made 
using the solution-state results as well as the CPMAS and NQS spectra. 
* 
200 180 160 140 120 100 80 
o /ppm 
60 40 
FcPl 
~ 
20 0 
Figure 3.30: CP and NQS 13C spectra of the r-form of indomethacin obtained at 
50.32 MHz, 13C frequency. The asterisks show the spinning sidebands. 
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It would seem that signals from C-12, C-13, C-15 and C-16 of indomethacin cannot 
be resolved, which may indicate rapid internal rotation on the NMR timescale of the 
phenylene group about its axis, even in the solid state at ambient temperature (which 
would render these carbons equivalent in pairs: C-12/16 and C-13/15). However, 
spectra at -80°C are not significantly different from those at 25°C (data not shown). 
Atom Solid-state Difference a 
numbers NMR/ppm /ppm 
19 179.1 6.9 
10 167.3 -0.6 
6 156.7 1.1 
14 139.0 ° 1.3 
2 131.2-137.4 -
11 131.2-137.4 -
12 131.2-137.4 -
16 131.2-137.4 -
4 131.2-137.4 -
9 131.2-137.4 
-
13 131.2-13 7.4 -
15 131.2-137.4 -
8 115.6 1.0 
3 112.6 -0.9 
7 112.6 1.2 
5 97.9 -3.8 
20 55.2 -0.2 
18 28.2 -1.4 
17 13.4 0.1 
• For the solution-state NMR chemical shifts, see table 3.1. The difference is from solid to solution. 
b Estimated to be at 139.0 ppm from a spectrum obtained using a Varian InfinityPlus 700 
spectrometer. 
Table 3.6: 13C SSNMR assignments ofthe y-form of indomethacin. 
The two main differences observed between solution-state and solid-state are for the 
carbon atoms 19 and 5. The difference for the carbon 19 is explained by the presence 
of a hydrogen bond. The difference for the carbon 5 can be explained by the fact that 
the methoxy group is not freely rotating along the aromatic-oxygen bond. Therefore, 
it is "fixed" into the position shown in table 3.6. This, in turn, changes the chemical 
shift of the carbon 5. 
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VT 13C SSNMR experiments have been carried out on crystalline indomethacin 
between 25°C and 150°C (data not shown). The spectra did not show any significant 
differences throughout the range of temperatures. 
2.2.1.3) Quadrupolar effect- Introduction 
When the 13C spectrum of indomethacin was acquired at 50.3 MHz, it was noticed 
that the resonance of the carbon attached to the chlorine atom, i.e. atom 14, had a 
peculiar shape. This arises from dipolar coupling to the quadrupolar chlorine nuclei. 
Chlorine nuclei have a non-zero electric quadrupole moment in the ground state. 
Such nuclei have transition frequencies between energy levels in the order of MHz in 
the absence of a magnetic field (nuclear quadrupole resonance). These transition 
energies are dependent on the nuclear quadrupole moment and the Electric Field 
Gradient (EFG) tensor at the nucleus. In the solid state in the presence of a magnetic 
field, the quadrupolar coupling is not averaged out by motion of the sample. Thus, 
MAS cannot completely remove its effects, even if spinning is infinitely fast. 
Therefore, the spectrum of, for example, a carbon attached to a chlorine atom will be 
broadened compared to that of a carbon that is not attached. The shape of this peak is 
also complicated by the fact the chlorine has two isotopes with spin >Yz, i.e. 35Cl and 
37 Cl. It was understood that for indomethacin parts of the C-CI bandshape were 
overlapped by other resonances. The same spectrum was acquired on the 300 MHz, 
500 MHz, 700 MHz and 800 MHz spectrometers, to see if further information could 
be obtained. It was clearly visible from these spectra that the higher the field the 
more defined the band of this carbon atom becomes, as expected. Nevertheless, the 
true chemical shift of this carbon was needed and this was achieved by theoretical 
computation. 
At high magnetic fields, when the quadrupolar interaction becomes less than the 
Zeeman interaction, perturbation theory may be invoked, and in the absence of scalar 
coupling a doublet splitting is predicted, as was indeed seen in the spectrum from the 
800 MHz spectrometer (figure 3.31). However, in principle, each component of the 
doublet is a powder pattern. Moreover, isotropic scalar coupling leads to additional 
splittings. Such additional splitting is apparent in the high-frequency component of 
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the 700 MHz spectrum. At lower magnetic fields, perturbation theory is no longer 
applicable and the spectra become more complex, but they can still be computed. 
142 141.5 141 140.5 140 139.5 
8/ppm 
139 138.5 138 137.5 137 
Figure 3.31: 800 MHz, 1H frequency, spectrum of indomethacin showing the signals 
for the carbon attached to the chlorine. 
2.2.1.4) Quadrupolar effect- Results 
All the theoretical results show the weighted effect of 35CI and 37 Cl. This was done 
by adding both theoretical spectra at the correct percentage, i.e. 75.77% for 35CI and 
24.23% for 37CI. 
A program called "anychi-0", supplied by A.C. Olivieri, was used to find the 
theoretical shape of the peak representing the carbon atom attached to the chlorine. 
This program assumes that the EFG is axially symmetric (i.e. in the principal axis 
system the x andy components are identical) and that the quadrupolar and dipolar 
vectors are co-axial. In order to use this program some parameters need to be 
defined. They are: 
- The quadrupolar coupling constant of the chlorine nuclei for this system (in 
MHz). 
- The resonance frequency of the chlorine nuclei at the magnetic field used (in 
MHz). 
- The isotropic coupling constant, J, (in units ofD). 
- The spectral width (in units ofD). 
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- The Gaussian width to be used in the convolution (in units of D). 
The dipolar coupling constant D between Be and 35Cl (or 37Cl) was calculated using 
equation 3.2: 
f..Lo 1 D=-hrcYct--2 -3 
4.1l' 4.1l' r 
Equation 3.2 
where 1-lo is the vacuum permeability, h is the Planck constant, Yc is the magnetogyric 
ratio of Be, YcJ is the magnetogyric ratio of 35Cl (or 37Cl), and r is the distance 
between the carbon and chlorine atoms. 
It is known that Yc is 6.7282840 x 107 rad s-1 T 1, YCJ is 2.624198 x 107 rad s-1 T 1 for 
35Cl and 2.184368 x 107 rad s-1 T 1 for 37Cl, and r is 1.735 x 10-10 m. This gave 
D =567Hz for 35Cl and D =472Hz for 37Cl. 
The quadrupolar coupling constant was first estimated using perturbation 
equation 3.3: 
10~VCI 
x= 3D Equation 3.3 
where ~ is half the splitting between the two peaks for the carbon attached to the 
chlorine (in Hz), vc1 is the frequency of 35Cl (or 37Cl) at a given magnetic field, and x 
is the quadrupolar coupling constant of 35Cl (or 37Cl). It should be noted that in 
principle, D should be written Derr. where D.ff = D- M . However, in this study it 
3 
was considered that ~J was negligible (but see later). Therefore, Detr~ D. 
It is known that the experimental value ~ at 700 MHz is 181Hz, measured between 
the maximum of the single peak and the highest-frequency part of the doublet, and 
vc1 is 68.66 MHz for 35Cl, at 700 MHz proton frequency. This gave x = -73 MHz, 
which is in reasonable accordance with the literatureB. From x, a value of R was 
calculated using the following equation: R = L 14• This gave a value of 1.06, which 
vs 
is slightly above that where perturbation theory applies (O<R<1). However, because 
the error is expected to be only ca. 1% the value of -73 MHz was used for further 
work. 
The value of Jc-CJ was needed. It was found in the literature15 that this is-20Hz for a 
chloroketosulfone. Therefore, this value was used in the computation before being 
optimised. A value of 5674 Hz was used for the spectrull! width and the Oaussian 
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width was set to 100 Hz. These values needed to be in units of D, thus they were as 
follows for 35Cl: 
- J: -0.035 units ofD for 35Cl, or -0.042 units ofD for 37Cl. 
- Spectrum width: 10 units ofD for 35Cl, or 12 units ofD for 37Cl. 
- Gaussian width: 0.176 units ofD for 35Cl, or 0.212 units ofD for 37Cl. 
This gave the theoretical spectrum shown in figure 3.32, but this did not fit well with 
the experimental spectrum. Therefore, the value of J was varied and, when using a 
value of -45 ± 5 Hz, the spectrum shown in figure 3.33 was simulated. It was then 
observed that the splitting between the singlet and the doublet was larger for the 
theory than the experiment. Therefore, the value of x and so the value of 11 were 
revisited. It was then decided to measure 11 between the maximum of the low 
frequency peak and the middle of the doublet. This gave a value of 11 of 156 Hz, 
which in tum, using equation 3.3, gave a value ofx of -63 MHz, for which a value of 
R was calculated to be 0.916, which fits with perturbation theory. The result is shown 
in figure 3.34. It was then observed that the splitting of the low field peak was 
slightly larger for the theory than for the experiment and the value of J was optimised 
again and found to be -43 Hz ± 5 Hz, though this value may be greater in error 
because the fit is not good. The result is shown in figure 3.35. 
-Theory 
-Experiment 
·-~------ --------·---------
146.48 144.48 142.48 140.48 138.48 136.48 134.48 132.48 130.48 
8 I PPll! 
Figure 3.32: Theory versus experimental at 175.96 MHz, 13C frequency, of C-14, 
J = -20 Hz and x = -73 MHz. 
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146.48 144.48 142.48 140.48 138.48 
o/ppm 
136.48 134.48 
· ·· Theocy 
-Experiment 
132.48 130.48 
Figure 3.33: Theory versus experimental at 175.96 MHz, Be frequency, of C-14, 
J =-45Hz and x = -73 MHz. 
-Theocy 
-Experiment 
146.48 144.48 142.48 140.48 138.48 136.48 134.48 132.48 130.48 
o/ppm 
Figure 3.34: Theory versus experimental at 175.96 MHz, Be frequency, of C-14, 
J == -45 Hz and x = -63 MHz. 
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~J~-45 Hz 
~J~-44 Hz 
~J=-43 Hz 
~J=-42 Hz 
~J=-41 Hz 
-J=-40 Hz 
-Experiment 
~~ ~~ \ 
v 
146.48 144.48 142.48 140.48 138.48 136.48 134.48 132.48 130.48 
8/ppm 
Figure 3.35: Theory versus experimental at 175.96 MHz, 13C frequency, of C-14, 
x=-63 MHz. 
The theory was then computed using the following values: 
- x=-63 MHz 
- Vci = 68.66 MHz for 35Cl, or 57.16 MHz for 37Cl. 
- J: -0.076 units ofD for 35Cl, or -0.091 units ofD, for 37Cl. 
- Spectrum width: 10 units ofD for 35Cl, or 12 units ofD for 37Cl. 
- Gaussian width: 0.176 units ofD, or 0.212 units ofD for 37Cl. 
The final result is shown in figure 3.36. This fitted reasonably the experimental 
observation. Then, the same computation was repeated at 200 MHz, 300 MHz, 
500 MHz and 800 MHz proton frequencies; the results are shown in figure 3.37. This 
is in good agreement with the experimental, see figure 3.38. The case-by-case 
comparison between the theory and the experimental at 200 MHz, 300 MHz, 
500 MHz and 800 MHz is shown in appendices 13, 14, 15 and 16 respectively. 
These calculations allowed to determine the true chemical shift of the carbon attach 
to the chlorine to be 139 ± 0.2 ppm. 
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It is possible that the splitting in the high-frequency doublet component at 700 MHz 
is an artefact arising from the relatively high noise level. A spectrum was obtained 
using an 800 MHz spectrometer (figure 3.31). Whilst this shows no such splitting, 
the available resolution is not good so the result is not definitive. Therefore, the main 
conclusion about scalar coupling is that its magnitude cannot be greater than 45 Hz, 
and the probable value is ca. -43 Hz. 
-Theory 
-Experiment 
146.48 144.48 142.48 140.48 138.48 136.48 134.48 132.48 130.48 
6 /ppm 
Figure 3.36£ Theory versus experimental at 175.96 MHz, 13C frequency, of C-14, 
J = -43 Hz and x = -63 MHz. 
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- 800MHz 
- 700MHz 
- SOOMHz 
- 300MHz 
200MHz 
R = 0.802 
R = 0.916 
R = 1.282 
R = 2.137 
~---~~ R = 3.206 
160 155 150 145 140 135 130 125 120 115 
o / ppm 
Figure 3.37: Theory at different magnetic fields, written as 1H frequency, of C-14, 
J = -43 Hz and x = -63 MHz. 
- 800MHz 
- 700MHz 
- SOOMHz 
- 300MHz 
- 200MHz 
160 155 150 145 140 
o / ppm 
135 130 
f\ 
f 
~
125 120 115 
Figure 3.38: Experimental at different magnetic fields, written as 1H frequency, of 
C-14. 
In the theory so far, it has been considered that ~J was zero, in accordance to 
perturbation theory. However, if this value is not zero some changes will be 
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observed. In the perturbation theory case, !::. is used to measure the value for xDerr, 
which is -36 x 109 Hz2, which was calculated using equation 3.3, where!::. was taken 
from the experiment at 700 MHz ctH frequency) for which Vet was 68.66 MHz. For 
this purpose, it was assumed that the observed value of!::. is dominated by the effect 
of the more abundant isotope, 35Cl.Note that in this study, D, rather than Derr, was 
used to calculate X· Therefore, if Derris less than D i.e. !::.J is positive, X will be bigger 
than 63 MHz, which is expected by comparison with the literature 13• 
2.2.1.5) T1H and T1pH measurements 
The measurements have been carried out, in duplicate, as stated in chapter Two using 
crystalline drug. The plots are shown in figure 3.39 and figure 3.40, for TtH and Tt/ 
respectively. The raw data are shown in appendix 17. 
The TtH measurements showed no minimum or maximum but a steady increase in 
the value of T 1 H with increasing temperature. This means that the measurements are 
on the high-temperature side of a Tt minimum. The slope gave an activation energy 
of 12.1 kJ mor1• It is good to note that all values of activation energy stated in this 
work should be taken as having an error of± 1 kJ.mor1• 
3 
2.5 
2 
0.5 
0 
A 
A 
-0.5 +---------,------..------,-------...------, 
5 4.5 4 3.5 3 2.5 
Figure 3.39: T1H measurements for crystalline indomethacin. The activation energy 
was calculated to be 12.1 kJ mort. 
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The T tp H measurements showed a minimum at 17 .8°C. The slope gave an activation 
energy of 38.0 kJ mort, between -30°C and 10°C, and 37.7 kJ mort, between 25°C 
and 80°C. These activation energies are presumably associated with an internal 
rotation along a single bond, but it is not possible to precisely define which single 
bond this corresponds to. 
In chapter One, it was seen that the minimum occurs when 'tc = 1/ro. In this case, it 
was calculated that 'tc = 20 ms, using ffit = 50 kHz. The values of Ea, 'tc and T minimum 
have now been calculated, and, by inserting these in equation 1.12, one can get the 
value for the pre-exponential factor, referred to as D. This value was calculated to be 
125.9 s. 
7 
A 
6.5 
6 
__.._ 5.5 
"' E A 
---:I: 
a. 5 
f-.:" 
'-' 
..5 4.5 A 
4 
A 
• 3.5 
A 
3 A 
5 4.5 4 3.5 3 2.5 
103/T I K 
Figure 3.40: Ttp H measurements for crystalline indomethacin. The activation energy 
was calculated to be 38.0 kJ mort for the low-temperature part, and 37.7 kJ mort for 
the high-temperature part. 
The difference in the activation energies between Tt and Ttp shows that two different 
motional processes are observed. It is, of course, expected that for a given motional 
process the Tt minimum will occur at a significantly higher temperature than the Ttp 
minimum. This is due to the fact that the minimum in Ttp depends on the frequency 
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yB1 rather then yBo. Therefore, for a given temperature range, T1 will reflect a lower-
barrier motional process than T1p, as observed. 
2.2.2) Nifedipine 
2.2.2.1) 1H spectrum 
A fast MAS 1H spectrum was acquired using the HX 2.5 mm probe on the 500 MHz 
spectrometer, see figure 3.41. The peak at 8.3 ppm is due to the amine proton, the 
shoulder at 7.4 ppm is due to the aromatic protons, the peak at 5.5 ppm is due to the 
methyne proton, the peak at 2.4 ppm is due to the methyl-ester groups and the 
shoulder at 1.5 ppm is due to the remaining methyl groups. 
20 15 10 5 
o/ppm 
0 -5 -10 
Figure 3.41: 1H spectrum of crystalline nifedipine, acquired at 500 MHz 
1H frequency, spinning at 27kHz. 
2.2.2.2) 13C spectra 
The De SSNMR spectrum of crystalline nifedipine was acquired using CPMAS and 
NQS (figure 3.43) techniques. The assignments, shown in table 3.7, were made using 
the solution-state results, as well as the CPMAS and NQS spectra. 
In the solution-state, the molecules are tumbling rapidly. Therefore, there is an 
apparent symmetry in the De spectrum. However, in the solid-state, this tumbling is 
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absent, so the symmetry is lost. This explains why the SSNMR spectrum looks more 
complicated than the solution-state one. Note that when this theory is considered one 
can confirm that there is only one molecule per asymmetric unit. 
The differences observed for the carbon atoms 7, 8, 9 and 10 are probably due to the 
geometry of the asymmetric unit. The aromatic ring is positioned in such a way that 
it is above the other ring in the same molecule and carbon atom 8 is the closest to this 
second ring, see figure 3.42. Therefore, the shift observed for this atom could be due 
to steric effects. 
Figure 3.42: Crystal structure of nifedipine showing that C-8 is above the non-
aromatic ring of the same molecule. 
Atom Solid-state Difference a 
numbers NMR/ppm /ppm 
3' 5' 169.9 168.1 
12 148.4 IJ 0.5 
2 6 149.4 144.8 IJ 
7 143 .9 IJ 1.2 
9 136.6 2.7 
8 135.7 4.4 
10 126.7 - 1.4 
11 124.1 - 0.2 
3 5 103 .1 101.6 
3", 5" 51.1 49.3 
4 35.4 0.8 
2', 6' 19.2 0.3 
• For the solution-state NMR chenucal shifts, see Table 3.4. The difference is from solid to solution. 
b Estimated from a spectrum obtained using a 500 MHz spectrometer. 
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Table 3.7: De SSNMR assignments of the modification I ofnifedipine. 
VT De SSNMR experiments have been carried out on crystalline nifedipine between 
25°C and 150°C (data not shown). The spectra did not show any significant 
differences throughout the range of temperatures. 
I J 1! 
_JL~Uj' 
200 180 160 140 120 100 
8/ppm 
* 
80 60 40 20 0 
Figure 3.43: CP and NQS De spectra of modification I of nifedipine obtained at 
50.32 MHz, 13C frequency. The asterisks show the spinning sidebands. 
For the carbon atoms 3' and 5', 3 and 5, and 3" and 5", the solution-state chemical 
shift is at a lower-frequency, in the middle and at a higher-frequency than that of the 
doublet, respectively. This is probably due to hydrogen bonding between the 
carbonyl oxygen and the NH group. 
One could see from figure 3.43 that the region from 130 ppm to 160 ppm is quite 
difficult to interpret. However, as stated in table 3.7, a 500 MHz spectrum was used 
to help the assignment. Figure 3.44 shows the spectra of crystalline nifedipine 
obtained at 125.68 MHz, 75.43 MHz and 50.32 MHz, 13C frequencies, between 130 
and 155 pm. It is easy to see the improvement in resolution as the strength of the 
magnetic field increases by looking at the doublet centred around 136 ppm. It is also 
visible that the group of peaks assigned to the carbons bonded to nitrogen atoms is 
getting easier to interpret. This could be explained by the fact that when a nitrogen 
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atom is bonded to a Be atom, the latter is subject to a 1:2 or 2:1 splitting. This 
influence of the nitrogen atom gets weaker as the magnetic field gets stronger, which 
can be observed in figure 3. 44. 
!55 !50 145 140 
()/ppm 
A 
I\ 
I I 
\ 
\ 
135 
-500 MHz 
-300MHz 
-200 MHz 
130 
Figure 3.44: 13C SSNMR spectra of crystalline nifedipine obtained at 125.68 MHz, 
75.43 MHz and 50.32 MHz, Be frequencies, showing only the region between 155 
ppm and 130 ppm. 
2.2.2.3) T1H and T1pH measurements 
The measurements have been carried out the same way as for indomethacin. The plot 
ofTtH is shown in figure 3.45. The T1pH data were not obtained. This was due to the 
long TIp H value and it was not possible to extend the spin-lock time array without 
damaging the probe; the array used went up to a value of 100 ms for the spin-lock 
time. The raw data are shown in appendix 18. 
The T 1 H measurements nifedipine showed no minimum or maximum but a steady 
increase in the value of T 1 H with increasing temperature, which helped to draw the 
same conclusions as for indomethacin. The slope gave an activation energy of 3.4 kJ 
mor
1
. 
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Figure 3.45: T 1H measurements for crystalline nifedipine. The activation energy was 
calculated to be 3.4 kJ mor1• 
2.2.3) Carbarnazepine 
2.2.3.1) 1H spectrum 
A fast MAS 1H spectrum was acquired using the HX 2.5 mm probe on the 500 MHz 
spectrometer, see figure 3.46. 
20 15 10 5 
c'\/ppm 
0 -5 -10 
Figure 3.46: 1H spectrum of crystalline carbamazepine, acquired at 500 MHz 
1H frequency, spinning at 27kHz using a pulse delay of60 s. 
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Figure 3.46 shows no resolved features and also shows that no hydrogen bond can be 
distinguished. 
2.2.3 .2) 13C spectra 
The Be SSNMR spectrum of crystalline carbamazepine was acquired using CPMAS 
and NQS (figure 3.47) techniques. The assignments, shown in table 3.8, were made 
using the solution-state results, as well as the CPMAS and NQS spectra. 
Atom Solid-state NMR I Difference a 
numbers ppm /ppm 
15 159.8 2.4 
1, 14 141.7, 139.5 
6, 9 134.7 - 0.5 
7, 8 131.1 0.4 
5, 10 129.3 -0.5 
3, 12 129.3 -0.4 
2, 13 129.3 0.3 
4, 11 127.5 -0.5 
• For the solution-state NMR, see Table 3.5. The difference is from solid to solution. 
Table 3.8: Be SSNMR assignments of modification ill of carbamazepine. 
* 
FcPl 
~ 
--------~-------
* 
200 180 160 140 120 100 80 60 40 20 0 
8 /ppm 
Figure 3.47: CP and NQS Be spectra of modification ill of carbamazepine obtained 
at 50.32 MHz, Be frequency . The asterisks show the spinning sidebands. 
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The large difference observed in table 3.8 for the carbon atom 15 is probably due to 
the fact that the CONH2 group is not freely rotating along the N-CONH2 bond. 
2.2.3.3) T1H and T1pH measurements 
The measurements have been carried out the same way as for indomethacin. The plot 
ofT1H is shown in figure 3.48. 
The T 1 H measurements for carbamazepine did not show any minimum or maximum. 
The rather small variation in the value ofT1H could be explained by limited mobility, 
which is consistent with the lack of conformational flexibility. This also did not 
allow the activation energy to be retrieved from this set of measurements. 
7 
6.8 
6.6 
6.4 
6.2 
,....._ 
"' ..._ 
:I: 6 A 
t: 
.s 5.8 A A 
A 
5.6 
5.4 
5.2 
5 
5 4.5 4 3.5 3 2.5 
Figure 3.48: T1H measurements for crystalline carbamazepine. No activation energy 
could be retrieved from this set of data. 
As for nifedipine, the T1/ data were not obtained but this problem was not present at 
high-temperature, i.e. above 70°C. However, only two points were recorded passed 
this temperature and, as a consequence, the T1p H graph was not plotted. The raw data 
ofthe T1H and T 1/ experiments are shown in appendix 19. 
79 
J 
Chapter Three: Crystalline Materials 
3/ Conclusions 
3 .1 I Materials 
It has been confirmed, using different analytical techniques, that the studied 
compounds were of they-form, modification I and modification III for indomethacin, 
nifedipine and carbamazepine respectively. 
3.2/ T1H and T1pH measurements 
The T1H measurements for indomethacin and nifedipine showed no minimum or 
maximum but a steady increase in the value ofT1H with increasing temperature. This 
means that these measurements are on the high-temperature side of a T 1 minimum. 
The slope gave an activation energy of 12.1 kJ mor' and 3.4 kJ mor' for 
indomethacin and nifedipine respectively, which clearly corresponds to different 
motional processes. They are sufficiently low (especially the latter) that they 
probably reflect internal rotation of a methyl group. 
The T1H measurements for carbamazepine did not show any minimum or maximum. 
The variation in the value ofT1H is quite small and this could be explained by limited 
mobility, which is consistent with the lack of conformational flexibility. No 
activation energy can be retrieved from this set of measurements. 
The T1p H measurements for indomethacin showed a minimum at 17.8°C. The slope 
gave an activation energy of 38.0 kJ mor' between -30°C and 10°C, and 
37.7 kJ mor' between 25°C and 80°C. These activation energies are presumably 
associated with an internal rotation along a single bond. However, it is not possible 
to precisely say which single bond this corresponds to. 
The difference in the activation energies between T1 and T1p, for indomethacin, 
shows that two different motional processes are observed. It is, of course, expected 
that for a given motional process the T1 minimum will occur at a significantly higher 
temperature than the T1p minimum, as the minimum in T1p depends on the frequency 
yB 1 rather then yB0• Therefore, for a given temperature range, T1 will reflect a lower-
barrier motional process than T1p, as observed. 
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3.3/ Quadrupolar effect 
The investigation done for the quadrupolar effect of the chlorine atom in 
indomethacin allowed the following information to be obtained: 
- The true 13C chemical shift ofC-14 is 139 ppm± 0.2 ppm. 
- The value of xDetr is -36 X 109 Hz2• 
- Jiso = ca. -43 Hz, which should be taken as a maximum magnitude. 
- x = -63 MHz, if it is considered that dJ is negligible. 
The sign of x should be given by the shape of low-field bands, but this is difficult to 
be certain of it given the problem of overlapping. However, the positions of the 
visible components at 200 and 300 MHz compare well with the theory in which the 
value of x is negative. Therefore, it is safe to assume that x is negative. 
81 
Chapter Three: Crystalline Materials 
4/ References 
I. N. Kaneniwa, M. Otsuka, and T. Hayashi. Physicochemical characterization of 
indomethacin polymorphs and the transformation kinetics in ethanol. Chern. 
Pharm. Bull. 33: 3447-3455 (1985). 
2. T. J. Kistenmacher and R. E. Marsh. Crystal and molecular structure of an 
antiinflammatory agent, indomethacin, 1-(p-chlorobenzoyl)-5-methoxy-2-
methylindole-3-acetic acid. J. Am. Chern. Soc. 94: 1340-1345 ( 1972). 
3. A. Burger and K. T. Koller. Polymorphism and pseudopolymorphism on 
nifedipine. Sci. Pharm. 64: 293-301 (1996). 
4. F. Hirayama, Z. Wang, and K. Uekama. Effect of2-hydroxypropyl-(f3)-
cyclodextrin on crystallization and polymorphic transition of nifedipine in solid 
state. Pharm. Res. 11: 1766-1770 (1994). 
5. A. M. Triggle, E. Shefter, and D. J. Triggle. Crystal structure of calcium channel 
antagonists: 2,6-dimethyl-3,5-dicarbomethoxy-4-[2-nitro-, 3-cyano-, 4-
( dimethylamino )-, and 2,3,4,5,6-pentatluorophenyl]-1 ,4-dihydropyridine. J. Med 
Chern. 23: 1442-1445 (1980). 
6. F. U. Krahn and J. B. Mielck. Relations between several polymorphic forms and 
the dihydrate of carbamazepine. Pharm. Acta Helv. 62: 24 7-254 (1987). 
7. A. L. Grzesiak, M. Lang, K. Kim, and A. J. Matzger. Comparison of the four 
anhydrous polymorphs of carbamazepine and the crystal structure of form I. J. 
Pharm. Sci. 92: 2260-2271 (2003). 
8. R. K. Harris, P. Y. Ghi, H. Puschmann, D. C. Apperley, U. J. Griesser, R. B. 
Hammond, K. Ma, K. J. Roberts, G. J. Pearce, J. R. Yates, and C. J. Pickard. 
Structural study of the polymorphs of carbamazepine, its dihydrate, and two 
solvates. Org. Process Res. Dev. 9: 902-910 (2005). 
9. W. Kemp. NMR in Chemistry, Macmillan, London, 1986, pp 76. 
82 
Chapter Three: Crystalline Materials 
I 0. D. H. Williams and I. Fleming. Spectroscopic methods in organic chemistry, 
McGraw-hill, Maidenhead, 1995. 
11. D. A. Fletcher, R. F. McMeeking, and D. Parkin. The United Kingdom chemical 
database service. J Chem. Inf Comput. Sci. 36: 746-749 (1996). 
12. R. J. Abraham. The analysis of high resolution NMR spectra, Elsevier, 
Amsterdam, 1971, pp 84-89. 
13. G. K. Semin, T. A. Babushkina, and G. G. Yakobsen. Applications ofNQR in 
chemistry, Khimiya, Leningrad, 1972. 
14. S. H. Alarc6n, A. C. Olivieri, S. A. Carss, R. K. Harris, M. J. Zuriaga, and G. A. 
Monti. Residual dipolar e5/ 7Cl, 13C) coupling in solid sodium chloroacetates. A 
combined variable-temperature 35Cl NQR and variable-field 13C MAS NMR 
study. J Magn. Reson. Ser. A 116: 244-250 (1995). 
15. K. Eichele, R. E. Wasylishen, J. S. Grossert, and A. C. Olivieri. The influence of 
chlorine-carbon dipolar and indirect spin-spin interactions on high resolution 
carbon-13 NMR spectra of chloroketosu1fones in the solid state. J Phys. Chem. 
99: 10110-10113 (1995). 
83 
-~ 
Chapter Four: Amorphous Materials- Confirmation 
Chapter Four: Amorphous Materials - Confirmation 
11 Results 
This chapter will look at the different methods used to produce amorphous materials 
and how it was checked that these materials were amorphous. This involved different 
analytical techniques, mainly XRPD and 13C SSNMR, which allowed one to look at 
different properties of the amorphous materials, and also at the effect of different 
timescales, due to the different techniques, on the study of these materials. This 
chapter will also look at the influence of the timescale on the recrystallisation 
phenomenon. 
1.11 Indomethacin 
1.1.1) DSC 
The amorphous sample was prepared as specified in chapter Two. The observed 
value of Tg was 45°C, see figure 4.1, which is consistent with the work of Forster et 
al. 1• This showed that amorphous indomethacin could be prepared using the melting 
and quench-cooling method. However, the amorphous phase was prepared using a 
small quantity of sample and it was necessary to see if the same preparation could be 
done on a bulk sample that would be needed for the SSNMR experiments. This 
experiment also showed that no recrystallisation occurs for amorphous indomethacin 
on the timescale of the DSC, and that no melting was observable, confirming the non 
recrystallisation ofthe sample. 
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Figure 4.1: DSC of amorphous indomethacin showing Tg at 45°C. 
1.1.2) FTIR 
A sample from a large-batch preparation of quench-cooled amorphous indomethacin 
was prepared and studied using FTIR. The FTIR spectrum obtained is shown in 
figure 4.2. 
It is observable that the FTIR of the crystalline and the amorphous forms (see figure 
4.3) are different. This difference is observed mainly by a broadening of the peaks, 
where the crystalline FTIR spectrum had narrower peaks. It is also apparent that 
some peaks are not present in the amorphous spectrum, for some of these it is just 
due to the broadening. One can also see that the wavenumbers of some of the 
vibrations are changed. This experiment showed that the quench-cooled method on a 
bigger scale worked for indomethacin. 
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Figure 4.2: FTIR of amorphous indomethacin. 
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Figure 4.3: FTIR spectra of amorphous (top) and crystalline (bottom) indomethacin, 
showing only the 700-1800 cm-1region. 
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1.1.3) Microscopy 
For indomethacin, microscopy was solely used in order to determine if the prepared 
amorphous sample was truly amorphous. This was done by looking at the crystalline 
sample to observe the presence of any birefringence. Then, the same was done with 
the amorphous sample. It was observed that the crystalline sample showed 
birefringence, see figure 4.4, while the amorphous sample did not show any all 
through the sample; this was assuming that the sample had not change to a cubic 
system. Therefore, it was concluded that the prepared sample was amorphous. 
Nevertheless, due to the minute amount of sample under examination it was not 
possible to confirm that a large sample was amorphous throughout. 
.. 
Figure 4.4: Polarised light microscopy snapshot of crystalline indomethacin, 
showing birefringence. 
13C SSNMR was used to check the amorphous character of the sample obtained 
using the method described in chapter Two. The peaks obtained using this technique 
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on the prepared sample showed that the sample was indeed amorphous, see figure 
4. 5. This is shown by the much broader lines obtained with the spectrum of the 
amorphous sample, see table 4.1. 
Crystalline material Amorphous material 
Chemical shifts I ppm Linewidths I Hz 
13.4 82 184 
55.2 77 161 
156.7 51 120 
Table 4.1: Lmew1dths of different smgle peaks obtamed from the crystalline and 
amorphous spectra of indomethacin. 
200 180 160 140 120 100 80 60 40 20 0 
i5 I ppm 
Figure 4.5: 13C SSNMR of crystalline and amorphous indomethacin obtained at 
50.32 MHz, Be frequency. 
This technique was also used in order to check the effect of grinding on amorphous 
sample. Figure 4.62 shows the Be SSNMR spectra of intact and ground amorphous 
indomethacin and nifedipine; the crushed amorphous samples were obtained by 
gentle grindin~ under liq1Jid nitrogen in a pestle artd mortar. It cancbe seen from this 
figure that indomethacin does not seem to recrystallise immediately after grinding. 
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Figure 4.6: 13C spectra at 74 MHz of indomethacin, (i) and (ii), and nifedipine, (iii) 
and (iv), quench-cooled melts at ambient probe temperature before, (i) and (iii), and 
after, (ii) and (iv), grinding.2 
13C SSNMR was also used in order to determine if amorphous indomethacin 
recrystallised on the timescale of an NMR experiment. From this experiment, see 
figure 4.7, it was observed that nothing occurred until a temperature of 90°C was 
reached, when the sample seems to recrystallise. However, this seemed to be a 
reversible effect because the recorded spectrum going back down to room 
temperature appeared more amorphous than crystalline. Therefore, it is possible to 
say that the sharpening is probably due to an increased molecular mobility rather 
than recrystallisation. The timing of the 13C VT SSNMR experiment for amorphous 
indomethacin is shown in table 4.2. 
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Figure 4.7: 13C VT SSNMR of amorphous indomethacin obtained at 50.32 MHz, 13C 
frequency. The crystalline spectrum is shown for reference. 
Temperature I Temperature reached Experiment started Experiment finished 
oc at I hr:min at I hr:min at I hr:min 
22 0:00 0:10 0:23 
30 0:28 0:38 0:51 
35 0:56 1:06 1:27 
40 1:32 1:42 2:03 
45 2:08 2:18 2:31 
50 2:36 2:46 3:07 
55 3:12 3:22 3:43 
60 3:48 3:58 4:19 
70 4:24 4:34 4:55 
80 5:00 5:10 5:52 
90 5:57 6:07 6:49 
22 6:54 7:14 7:35 
13 Table 4.2: Ttmtng used for the C VT SSNMR expenment performed on 
amorphous indomethacin. 
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1.1.5) XRPD 
At first, XRPD was used to determine the amorphous character of the prepared 
sample. Figure 4.8 shows that the prepared sample is definitely amorphous as only a 
halo of low counts value is visible, which is characteristic of an amorphous sample as 
a halo is due to a lack of long range order. 
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Figure 4.8: XRPD of amorphous indomethacin at room temperature. 
XRPD was also used to study the physical stability of amorphous indomethacin (data 
not shown). This was done by looking at an intact and at a ground sample; each 
samples had two specimens one kept at room temperature, 20°C to 25°C, and one 
kept in the freezer, -l5°C to -20°C. Both intact samples, as well as the ground sample 
kept in the freezer, showed no sign of recrystallisation after a week. However, the 
ground sample kept at room temperature started to recrystallise after a day, while it 
showed no sign of recrystallisation straight after the preparation; this is consistent 
with what was observed using SSNMR. This showed that in order to keep a sample 
of amorphous indomethacin from recrystallising, one should either keep it intact or 
ground and in the freezer. This is in agreement with the work ofFukuoka et al.3 who 
observed the rapid recrystallisation of pulverised glassy indomethacin and also that 
intact glassy indomethacin was stable and recrystallisation did not occur for more 
than 2 years at room temperature. 
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This method was further used with VT equipment to see if any recrystallisation was 
appearing over a range of temperature similar to the one used for the 13C VT SSNMR 
and following a similar time scale as for the relaxation times measurements, see 
chapter Five. Figure 4.9 shows the XRPD VT experiment. This experiment showed 
no recrystallisation throughout the range of temperature -70°C to 80°C, which is in 
agreement with the 13C SSNMR VT experiment. Note that no real change is visible 
throughout the XRPD VT experiment, whilst there is an apparent change in mobility 
observed when looking at the 13C SSNMR VT experiment. This difference can be 
explained by the fact that the mobility of amorphous samples will not be apparent in 
XRPD. 
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Figure 4.9: VT XRPD experiment of amorphous indomethacin. 
1.2/ Nifedipine 
1.2.1) DSC 
The amorphous sample was prepared as specified in chapter Two. The value of Tg 
observed is 46°C, see figure 4.10, which is consistent with the work of Aso et al.4 . 
The same conclusions as for indomethacin on the preparation of the amorphous 
sample apply for nifedipine. This experiment, see figure 4.10, also showed that 
recrystallisation occurs for amorphous nifedipine from 104°C and appears to go 
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through different phases. This was shown by Burger and Koller5, and also by 
Keymolen et a1.6, to be the crystallisation of modifications III and II as well as the 
transition from modification III to modification II, followed by the transition from 
modification II to modification I and the melting of the rest of modification III. 
Burger and Koller5 used thermomicroscopy to determine this, and in this study 
amorphous nifedipine was also examined using hot-stage microscopy, as shown in 
part 1.2.3 of this chapter. 
The diffractogram ends by the recrystallisation of the sample into modification I, 
which then melts at 173°C. This is the same value as seen in figure 3.5. 
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Figure 4.10: DSC of amorphous nifedipine, showing the Tg, at 46°C, the 
recrystallisation, at 104 °C, and the melting, at 173 °C. 
Another DSC experiment was carried out using amorphous nifedipine in order to 
study the recrystallisation process. This experiment consisted of forming an 
amorphous sample and then reheating this sample at different speeds. 
The following method was applied to the sample: 
1. Heat from 20°C to 180°C at a rate of 40°C/min. 
2. Hold at 180°C for 1 min. 
3. Cool from 180°C to 20°C at a rate of 40°C/min. 
4. Heat from 20°C to 180°C at a rate of X°C/min, where x was set to 10, 30, 50, 
70, 100, 150, 200, 250 and 300. 
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This study showed that at a reheating rate of 1 0°C/min, the stable form of nifedipine 
was the major form present. But, when using a reheating rate of 30°C/min, the 
metastable form was also present in a significant quantity as the endothermic peaks 
of both forms were of similar area. At 50°C/min and 70°C/min, the metastable form 
was the major one. It was also observed that at a reheating rate of 1 00°C/min, and 
above, the recrystallisation did not occur. This gives a guide as how to prepare the 
metastable form of nifedipine. It also let one see that during the VT process, one 
should be careful about the temperature at which the sample is reheated. This is 
illustrated in figure 4.11. 
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Figure 4.11: DSC of amorphous nifedipine, reheating rate ofx°C/min, where xis 10, 
30, 50, 70 and 100. 
1.2.2) FTIR 
A sample of quench-cooled amorphous nifedipine was prepared and studied using 
FTIR, see figure 4.12. 
It is observable that the FTIR of the crystalline and amorphous forms (see figure 3.6 
and figure 4.12 respectively) show similar differences when compared to those seen 
between crystalline and amorplious indometliaCin, i.e. the cryst~fiin~ sample -shmvs 
sharp bands while the amorphous sample shows broad bands. This showed that the 
quench-cooled method worked on a bigger scale for this compound also. 
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Figure 4.12: FTIR of amorphous nifedipine. 
1.2.3) Microscopy 
In the case of nifedipine, two kinds of microscopy were used. Polarised light 
microscopy was used in order to check the amorphous character of the prepared 
sample, see figure 4.13, and hot-stage microscopy, data not shown, was used in order 
to understand the process involved during the recrystallisation. 
For the hot stage microscopy, the amorphous sample was heated from room 
temperature at a rate of 1 ooc I min until the start of the recrystallisation. At this 
point, the rate was lowered to 5°C I min. It was observed that the sample was going 
through different recrystallisation processes during the recrystallisation, which is in 
agreement with the work of Burger and Koller5• This could explain the complexity of 
the recrystallisation exotherm observed in figure 4.1 0. 
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Figure 4.13: Polarised light microscopy snapshot of crystalline nifedipine showing 
birefringence. 
Polarised light microscopy was used on both crystalline and amorphous samples, and 
both were checked for the presence of birefringence. As for indomethacin, only the 
crystalline sample showed birefringence, see ftgure 4.13 . Therefore, it was concluded 
that the prepared sample was amorphous. Nevertheless, it was not possible to say that 
a bulk sample was amorphous throughout, as explained for indomethacin. 
1.2.4) 13C SSNMR 
13C SSNMR was used to check the amorphous character of the sample obtained 
using the method described in chapter Two. The 13C SSNMR spectrum of this 
sample showed very broad peaks when compared to the crystalline form, see ftgure 
4.14, which implies that the prepared sample was amorphous. Table 4.3 shows the 
comparison of the linewidths of some peaks between the crystalline and the 
amorphous spectra. 
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Figure 4.14: Be SSNMR of crystalline and amorphous nifedipine obtained at 
50.32 MHz, Be frequency. 
Crystalline material Amorphous material 
Chemical shifts I ppm Linewidths I Hz 
19.2 44 204 
35.4 44 166 
Table 4.3: Lmewtdths of dtfferent smgle peaks obtamed from the crystalline and 
amorphous spectra of nifedipine. 
Figure 4.62 shows the 13C SSNMR spectra of intact and ground amorphous 
nifedipine. It can be observed from this figure that the ground sample is a mixture of 
broad lines (resembling the amorphous spectrum) and sharp resonances (resembling 
the crystalline spectrum) which indicate that grinding of glassy nifedipine causes 
recrystallisation. 
This technique was also used to determine if amorphous nifedipine recrystallised on 
the timescale of an NMR experiment, see figure 4.15. The temperature was raised 
from room temperature to 65°C stttad!ly. It wa~ observed that some changes started 
to occur around this temperature. Therefore, a series of spectra was acquired at this 
temperature until no further change was observed. The obtained spectra were seen to 
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show recrystallisation into modification I. The temperature was then lowered back to 
room temperature in order to check for reversibility. However, the spectra obtained 
at 65°C and back at room temperature were similar and were comparable to that of a 
genuinely crystalline sample, proving a non-reversible phenomenon. The timing of 
the 13C VT SSNMR experiment for amorphous nifedipine is shown in table 4.4. 
- Crystalline 
-25°C 
- 65°C (last) 
- 65°C (first) 
- 60°C 
- 25°C 
- -40°C 
200 180 160 140 120 100 80 60 40 20 0 
8 I ppm 
Figure 4.15: 13C VT SSNMR of amorphous nifedipine obtained at 50.32 MHz, 
13C frequency . The crystalline spectrum is shown for reference. 
Temperature I Temperature reached Experiment started Experiment finished 
oc at I hr:rnin at I hr:min at I hr:min 
-40 0:00 0:20 1:03 
0 1:08 1:28 2:11 
25 2:16 2:36 2:57 
35 3:02 3:12 2:33 
45 3:38 3:48 4:09 
55 4:14 4:24 4:45 
60 4:50 5:00 5:21 
65 (first) 5:26 5:36 5:57 
65 (last) NIA 8:51 9:12 
25 9:17 9:37 9:58 
. 1. Table 4.4. Ttmmg used for the C VT SSNMR expenment performed on 
amorphous nifedipine. 
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1.2.5) XRPD 
Figure 4.16 shows the XRPD diffractogram of amorphous nifedipine, which shows 
that the prepared sample is definitely amorphous as only a halo of low counts values 
is visible. 
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Figure 4.16: XRPD of amorphous nifedipine at room temperature. 
This technique was also used in order to look at the stability of amorphous nifedipine 
under different conditions. This study consisted in acquiring the diffractograms (data 
not shown) of three samples of amorphous nifedipine; one intact kept in the freezer 
and two ground samples, kept in the same conditions as for indomethacin. It was 
observed than the ground samples showed sign of recrystallisation straight after 
preparation, supporting earlier XRPD7 and SSNMR2 findings. However, the intact 
sample showed no sign or recrystallisation after one week. Therefore, one should 
keep amorphous nifedipine intact and in the freezer. 
XRPD was further used with VT equipment to see if any recrystallisation was 
appearing over a range of temperatures similar to the one used for the 13C VT 
SSNMR, and using a similar timescale as for the relaxation times measurements, see 
chapter Five. The result of this experiment is shown on figure 4.17 and it can be seen 
that recrystallisation occurred between 60°C and 80°C and that it is a non-reversible 
phenomenon. 
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Figure 4.17: VT XRPD experiment of amorphous nifedipine. 
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Following the results of this experiment, it was decided to carry out a similar 
experiment using increments of 5°C, see figure 4.18, rather than following the 
temperatures used for the 13C SSNMR experiment. The timing for this last 
experiment is shown in table 4.5 . 
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Figure 4.18: VT XRPD experiment of amorphous nifedipine. 
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Temperature I Temperature reached Experiment started Experiment finished 
oc at I hr:min at I hr:min at I hr:min 
27 0:00 0:10 0:24 
15 0:25 0:35 0:49 
20 0:50 1:00 1:14 
25 1:15 1:25 1:39 
30 1:40 1:50 2:04 
35 2:05 2:15 2:29 
40 2:30 2:40 2:54 
45 2:55 3:05 3:19 
50 3:20 3:30 3:44 
55 3:45 3:55 4:09 
60 4:10 4:20 4:34 
65 4:35 4:45 4:59 
70 5:00 5:10 5:24 
75 5:25 5:35 5:49 
80 5:50 6:00 6:14 
27 6:19 6:39 6:53 
Table 4.5: Timing used for the second VT XRPD experiment performed on 
amorphous nifedipine and amorphous carbamazepine. 
1.3/ Carbamazepine 
1.3.1) DSC 
The amorphous sample was prepared as specified in chapter Two. The value of Tg 
observed is 57°C, see figure 4.19, which is in agreement with the work of Patterson 
et al.8• The same conclusions as for indomethacin on the preparation of the 
amorphous sample apply for carbamazepine. The DSC also showed that amorphous 
carbamazepine recrystallised to modification I from around 104°C, which then melts 
at around 186°C. It was understood that the amorphous form recrystallised 
predominantly to modification I as the endothermlexotherm observed at around 
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l75°C for the crystalline material is not present and also because modification I is 
the stable form at elevated temperature. However, the onset of the melting observed 
for the recrystallised amorphous form is lower, 186°C, than that expected for the 
crystalline form, 192°C (see figure 3.8). This could be explained by the presence of 
other polymorphic forms, impurities or incomplete recrystallisation. 
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Figure 4.19: DSC of amorphous carbamazepine, showing the Tg at 57°C, 
recrystallisation at 104°C and melting at 186°C. 
1.3.2) FTIR 
A sample of quench-cooled amorphous carbamazepine was prepared and studied 
using FTIR, see figure 4.20. 
It is observable that the FTIR of the crystalline form shows sharper bands than the 
amorphous forms (see appendix 4 and figure 4.20 respectively) and also that some 
differences are seen in the fingerprints. This showed that the quench-cooled method 
on a bigger scale worked for carbamazepine. 
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Figure 4.20: FTIR of amorphous carbamazepine. 
1.3.3) 13C SSNMR 
The 13C SSNMR was used in order to check the amorphous character of the sample 
obtained using the method described in chapter Two. The broadness of the peaks 
obtained for the amorphous form compared to the crystalline form showed that the 
sample was amorphous, see figure 4.21. 
This technique was also used in order to determine if amorphous carbamazepine 
recrystallised on the timescale of an NMR experiment. It is observable that the peaks 
start to sharpen at 75°C and that this process is not reversible. Even though this 
sharpening does not lead to a truly crystalline phase, it still showed that 
carbamazepine started to recrystallise within the timescale of this experiment. 
The timing of the 13C VT SSNMR experiment for amorphous carbamazepine is 
shown in table 4.6 
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Figure 4.21: Be SSNMR of crystalline and amorphous carbamazepine obtained at 
50.32 MHz, Be frequency. 
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Figure 4.22: Be VT SSNMR of amorphous carbamazepine obtained at 50.32 MHz, 
Be frequency. The crystalline spectrum is shown for reference. 
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Temperature I Temperature reached Experiment started Experiment finished 
oc at I hr:min at I hr:min at I hr:min 
-40 0:00 0:20 0:31 
0 0:36 0:56 1:07 
25 1:12 1:32 1:43 
35 1:48 1:58 2:09 
45 2:14 2:24 2:35 
55 2:40 2:50 3:01 
65 3:06 3:16 3:27 
75 3:32 3:42. 3:53 
25 3:58 4:18 4:29 
I Table 4.6: T1mmg used for the C VT SSNMR expenment performed on 
amorphous carbamazepine. 
1.3.4) XRPD 
Figure 4.23 shows the XRPD diffractogram of amorphous carbamazepine. From this 
figure it is visible that the prepared sample is amorphous as only a halo of low counts 
values is visible. 
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Figure 4.23: XRPD of amorphous carbamazepine at room temperature. 
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This method was further used with VT equipment to see if any recrystallisation was 
appearing over a range of temperatures similar to the one used for the 13C VT 
SSNMR, and following a similar time scale to that shown in chapter Five for the 
relaxation times measurements. The result ofthis experiment is shown in figure 4.24 
and it shows that recrystallisation occurred between 60°C and 80°C. Furthermore, it 
is possible to say that this phenomenon is non-reversible as the diffractogram 
obtained when going back down in temperature still shows substantial signs of 
crystallinity. 
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Figure 4.24: VT XRPD experiment of amorphous carbamazepine. 
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Following the results of this experiment it was decided to carry out a similar 
experiment using increments of S°C, see figure 4.2S, rather than following the 
temperatures used for the 13C SSNMR experiment. The timing for this last 
experiment is shown in table 4.S. One can see that signs of recrystallisation are 
observable from 6S°C and are more evident at 70°C and 7S°C, at which point the 
process seems to be complete as no significant differences can be observed between 
the ditfractograms at 7S°C and 80°C. The temperature at which the recrystallisation 
starts to occur is consistent for both XRPD and 13C SSNMR. 
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Figure 4.25: VT XRPD experiment of amorphous carbamazepine. 
2/ Conclusions 
It has been observed that all three compounds of interest can easily be made 
amorphous by a simple quench-cooling process. It was also shown that amorphous 
indomethacin could be kept either intact at room temperature or in the freezer, or 
ground and in the freezer, while amorphous nifedipine should be kept intact and in 
the freezer. Furthermore, it was seen that, once amorphous, these compounds behave 
in different ways. It was observed that amorphous indomethacin did not seem to 
recrystallise in the timescale of the SSNMR and XRPD experiments up to a 
temperature of 80°C but a reversible phenomenon, possibly due to an increase in 
molecular mobility, was observed, using 13C SSNMR, at 90°C. However, both 
amorphous nifedipine and amorphous carbamazepine seem to recrystallise at a 
temperature of about 65°C. These observation were consistent between XRPD and 
13C SSNMR techniques. 
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11 Results 
This chapter will look at the results obtained on the amorphous form of the studied 
drugs using 1H SSNMR. This will involve studying the proton bandshapes as a 
function of temperature in order to gain more understanding of the recrystallisation 
process. It will also involve looking at the T1H and T1pH values obtained over a wide 
range of temperature in order to gain information on the molecular-level motions. 
The data obtained with the 300 MHz spectrometer was the work of D.C. Apperley1 
and is shown here for comparative purposes. 
1.1 I Proton bandshapes 
The proton bandshapes of the amorphous samples were studied over a range of 
temperatures past the Tg in order to obtain information about the recrystallisation 
phenomenon at high temperatures. The spectra were recorded using a one-pulse-and-
acquire pulse sequence. 
The proton bandshapes were also recovered, as secondary information, from the T 1 H 
and T 1 PH experiments, more precisely from the last spectrum of the array for T 1 H and 
the first spectrum of the array for T1p H. They were then analysed in order to obtain 
more information on the way the sample behaves over a wider range of temperature. 
The last spectrum of the array for the T 1 H measurements was used as this is the 
spectrum where the recovery time allowed the system to be back to complete 
equilibrium. Therefore, after this recovery time, one is actually in the presence of a 
simple one-pulse-and-acquire pulse sequence on a sample at equilibrium. 
Furthermore, the first spectrum of the array for the T 1/ experiment was also used as 
this is the spectrum where the spin-lock time is the shortest. Thus, the spectrum 
acquired is as close as possible to one that would have been obtained using a pulse-
and-acquire pulse sequence. 
In this chapter, only the proton bandshapes obtained from the T1H are shown since 
the T1H and T1pH experiments, as expected, yielded similar spectra. 
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1.1.1) Indomethacin 
The static 1H VT SSNMR spectra of amorphous indomethacin obtained by pulse-
and-acquire are shown in figure 5 .1. The timing for this experiment is shown in table 
5.1. Figure 5.1 shows that, when heating from ambient temperature up to 70°C, only 
a sharpening of the peak is visible. However, from 90°C upwards a very sharp set of 
peaks is visible without any other broad peaks. This shows that there is rapid motion 
in the amorphous solid, probably due to some amorphous sample having not yet 
recrystallised. 
The spectra at 120°C and 150°C are similar, and were compared to the high-speed 
MAS 1H SSNMR spectra obtained for the crystalline material (see figure 3.29). 
-----~-----
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8/ppm 
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Figure 5.1: Static 1H VT SSNMR spectra of amorphous indomethacin obtained by 
single-pulse-and-acquire at 200.13 MHz, 1H frequency. 
Figure 5.2 shows the proton bandshapes obtained from the last spectrum of the T1H 
array at different temperatures for amorphous indomethacin. The timing for the 
experiment is shown in table 5.2. The timing was matched to within two hours 
between the different series of experiments. 
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Temperature I Temperature reached Experiment started Experiment finished 
oc at I hr:min at/ hr:min at I hr:min 
50 0:00 0:20 0:23 
70 0:28 0:48 0:51 
90 0:57 1:17 1:20 
120 1:25 1:45 1:48 
150 1:54 2:14 2:17 
Table 5.1: Timing used for the 1H VT SSNMR experiment performed on amorphous 
indomethacin. 
It is seen from figure 5.2 that no real changes, apart from a slight sharpening, occurs 
for the proton bandshape for temperatures between -70°C and 50°C, apart :from a 
slight sharpening at 50°C, i.e. past Tg. However, at 60°C the sharpening is increased 
and from 80°C only a single, relatively sharp peak is visible. This shows a change in 
mobility, probably arising :from non-recrystallised amorphous parts in the sample, 
which is in accordance with that observed in figure 5 .1. Note that the splitting of the 
sharp peak was observable in figure 5.1 but does not seem to appear in figure 5 .2. 
This is explained by the change in the scale of the x-axis between the two figures. 
300 250 200 150 100 
kHz 
50 0 -50 -100 
120°C 
-uooc 
- l00°C 
-90°C 
-sooc 
-60°C 
-50°C 
-40°C 
-30°C 
-20°C 
-ooc 
--30°C 
--50°C 
--70°C 
Figure 5.2: Proton bandshapes obtained from the last spectrum of the T 1H array. at 
diffe~ent temperatures for amorphous indomethacin. The horizontal scale is for 
reference only. 
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At the highest temperature, a very broad signal can be seen underlying the sharp 
peak. This may be ascribed to recrystallised indomethacin, which is relatively rigid. 
Such a spectrum was also obtained, earlier, by Dr. Apperley1• The broad underlying 
signal is not visible in figure 5.1, probably because the total time taken for the pulse-
and-acquire spectra is significantly less than that for the T1H experiment. 
Temperature I Temperature reached Experiment started Experiment finished 
oc at I hr:min at I hr:min at I hr:min 
-70 0:00 0:20 0:28 
-50 0:33 0:48 0:54 
-30 0:59 1:14 1:25 
0 1:30 1:45 2:00 
20 2:05 2:20 2:43 
30 2:48 2:58 3:24 
40 3:29 3:39 4:05 
50 4:10 4:20 4:42 
60 4:47 4:57 5:21 
80 5:26 5:41 6:02 
90 6:07 6:17 6:30 
100 6:35 6:45 6:55 
110 7:00 7:10 7:42 
120 7:47 7:57 8:41 
Table 5.2: Timing used for the T1H and T1pH experiments performed on amorphous 
indomethacin. The experiment times include both experiments. 
1.1.2) Nifedipine 
The static 1H VT SSNMR spectra of amorphous nifedipine obtained by pulse-and-
acquire are shown in figure 5.3. The timings for this experiment is shown in table 
5.3. The figure shows that the peak is sharpening a lot between 50°C and 70°C, 
probably due to more mobility in the amorphous phase. However, at 90°C 
significantly broader peak with a sharp peak on top of it appears. This could be 
explained by a two-phase system where both the amorphous and the crystalline 
phases are present. It is clear that the recrystallisation is significantly easier (and 
occurs at a lower temperature) for nifedipine than for indomethacin. This 
phenomenon was described briefly in chapter Four and in more detail by Burger and 
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Kolle~. The sharp peak is more and more defined as the temperature rises form 90°C 
to 150°C. This sharp peak might be due to residual amorphous domains that are 
difficult to recrystallise. 
200 150 100 50 0 
8/ppm 
-50 -100 -150 -200 
Figure 5.3: Static 1H VT SSNMR spectra of amorphous nifedipine obtained by 
single-pulse-and-acquire at 200.13 MHz, 1H frequency. 
Temperature I Temperature reached Experiment started Experiment finished 
oc at/ hr:min at I hr:min at I hr:min 
50 0:00 0:20 0:28 
70 0:33 0:53 1:01 
90 1:06 1:26 1:34 
120 1:39 1:59 2:07 
150 2:12 2:32 2:38 
I· Table 5.3: T1mmg used for the H VT SSNMR expenment performed on amorphous 
nifedipine. 
Figure 5. 4 shows the proton bandshapes obtained from the last spectrum of the T 1 H 
array at different temperatures for amorphous nifedipine. The timing for the 
experiment is shown in table 5.4. The timing was matched to within two hours 
between the different series of experiments. The difference observed in the shape of 
the peak between figure 5.3 and figure 5.4 is due to the fact that the total time taken 
f~r . the pulse-and,-,acquire spectra -is significantly less than that for the T i H 
experiment. 
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Figure 5.4 shows that there is little change until 80°C is reached when a sharp peak, 
with a broad peak under it, is visible. It would seem that ~ecrystallisation has not 
occurred up to 60°C. It may have done so to some extent at 80°C, but this is hard to 
see, the sharp peak presumably arising from increased mobility in amorphous 
domains. 
300 250 200 150 100 
kHz 
50 
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Figure 5.4: Proton bandshapes obtained from the last spectrum of the T 1 H array at 
different temperatures for amorphous nifedipine. The horizontal scale is for reference 
only. 
Temperature I Temperature reached Experiment started Experiment finished 
oc at I hr:min at I hr:min at I hr:min 
-70 0:00 0:20 0:33 
-40 0:38 0:58 1:10 
-10 1:15 1:35 1:48 
10 1:53 2:13 2:27 
25 2:32 2:52 3:07 
30 3:12 3:22 3:37 
40 3:42 3:52 4:07 
50 4:12 4:22 4:38 
60 4:43 4:53 5:09 
80 5:14 5:34 5:48 
H H Table 5.4: T1mmg used for the T 1 and T tp expenments performed on amorphous 
nifedipine. The experiment times include both experiments. 
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1.1.3) Carbamazepine 
The one-pulse-and-acquire pulse sequence was not used to obtain information on the 
proton bandshape as this compound has a very long T1H value (more than 300 s), as 
discussed in chapter One. However, the bandshape could still be recovered from the 
T1H and T1pH experiments and the series of spectra obtained from the T1H case is 
shown in figure 5.5. The timing for this experiment is shown in table 5.5. The timing 
was matched to within two hours between the different series of experiments. 
The proton bandshapes shown in figure 5.5 seem to be composed of a peak 
surrounded by two "wings". These "wings" resemble a Pake doublet and from this 
doublet it is possible to see that ~D. is 38.4 kHz yielding a proton to proton radius 
2 
of 0.167 nm. This value does not fit with any of the proton-proton distances observed 
for carbamazepine. However, it does fall between the H-H value for the amino group 
and that of the two protons on the 7 -atoms ring, 0.156 nm and 0.229 nm respectively. 
The fact that the calculated value is "in between" is expected as both distances are 
present in the molecule. 
Figure 5.5 shows that the proton bandshape of amorphous carbamazepine does not 
change much between -70°C and 55°C. However, a sharpening is observable from 
65°C, which is consistent with the VT XRPD study shown in figure 4.20, and is 
consistent with expectations as the sample is heated above Tg. The sharpening is 
more pronounced at 75°C, even more at 85°C and finally a really sharp peak is 
observed at 1 05°C. 
As for indomethacin and nifedipine, the sharp peak is associated with amorphous 
domains that have not yet recrystallised, while the underlying broad peak at 85°C 
and 1 05°C probably arises from the recrystallised sample. One can also see that the 
area of the sharp peak gets smaller as the temperature rises. This is probably due to 
the fact that the recrystallisation is more and more complete, i.e. that the 
non-recrystallised amorphous is becoming crystalline. This seems to be in 
accordance with what was observed in chapter Four, i.e. that amorphous 
carbamazepine starts to recrystallise around 65°C and this phenomenon is still going 
on at 80°C. From this study, it can be seen that the recrystallisation phenomenon is 
still being under way at 105°C when using the timing shown below. 
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Figure 5.5: Proton bandshapes obtained from the last spectrum of the T 1 H array at 
different temperatures for amorphous carbamazepine. The horizontal scale is for 
reference only. 
Temperature I Temperature reached Experiment started Experiment finished 
oc at I hr:min at I hr:min at I hr:min 
-70 0:00 0:20 0:59 
-30 1:04 1:24 1:54 
10 1:59 2:19 2:53 
25 2:58 3:18 3:50 
35 3:55 4:05 4:39 
45 4:43 4:53 5:27 
55 5:32 5:42 6:16 
65 6:21 6:31 7:04 
75 7:09 7:19 7:49 
85 7:54 8:04 8:28 
105 8:33 8:53 9:56 
Table 5.5: Timing used for the T 1 H and T 1p H experiments performed on amorphous 
carbamazepine. The experiment times include both experiments. 
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1.2/ T1H and T1pH measurements 
The measurements have been carried out, at the miniumum, in duplicate using the 
amorphous drug which was prepared according to the protocol shown in 
chapter Two. 
In the case of the crystalline materials, the activation energies were retrieved from 
the slopes of the T1H and T1/ curves because in such a case only a single specific 
type of motion appears to be involved. However, there are circumstances when 
meaningful activation energies cannot be retrieved from the slope. This can be due to 
the presence of several motions of similar activation energies. In the case of 
amorphous materials, it is likely that complications arise due to the fact that for any 
given motion a range of activation energies is expected as the intermolecular 
interactions will vary with the local environment which is variable throughout an 
amorphous sample. In both of these cases, the situation would involve overlapping 
minima, giving a broad and shallow minimum, if any minimum is visible at all. As a 
result, the slopes would not properly reflect the activation energies. 
Srcic et al. 3 showed that SSNMR could be used to confirm the amorphous nature of a 
sample by looking at T1 for both the crystalline and amorphous materials; it appears 
that the closer the sample gets to its melting point the greater the difference in T 1 
between the crystalline and amorphous materials becomes. They used this as a proof 
that they had formed glassy felodipine. However, the relaxation time study in this 
thesis was well below the melting point of the drugs, and as such it is difficult to 
assess the amorphous character of any of the compounds using SSNMR. 
1.2.1) Indomethacin 
Figure 5.6 shows the T1H curve, as a function of the temperature, obtained for 
amorphous indomethacin. The raw data are given in appendix 20. It is clearly visible 
from the figure that the trends in T1H have similar behaviour at different magnetic 
fields, as one could expect. However, as T1H is dependent on the Larmor frequency, 
the change of strength of the magnetic field influences its value, as demonstrated in 
figure 5.6. 
From this figure, it can be seen that a maximum appears around Tg at ca. 45°C (Tg 
was measured, using DSC, to be 45°C for amorphous indomethacin, see figure 4.1). 
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The maximum appears after a steady increase in the T 1 H value from -70°C which 
could indicate recovery from a T 1 H minimum at or below -70°C. If one compares the 
slopes obtained from the crystalline material to those obtained from the amorphous 
material, it can be seen that they follow a similar trend before Tg. It is also noticeable 
that the T 1H value is slightly lower for the amorphous than for the crystalline, which 
is expected as the former is likely to be somewhat more mobile than the latter. Above 
Tg, the values ofT 1H drop sharply as generalised motion occurs. This observation is 
consistent with the linewidth decreases mentioned above, but is apparent at lower 
temperatures. 
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Figure 5.6: T 1 H measurements for amorphous indomethacin. The maximum IS 
observed at Tg (45°C). 
Figure 5.7 shows the T1pH curve, as a function of the temperature, obtained for 
amorphous indomethacin. The raw data are given in appendix 20. 
It is clearly visible from the figure that T 1p H behaves similarly at different magnetic 
fields. This is fortuitous, as the nutation frequency was set to different values (50 
kHz and 70kHz at 200 MHz and 300 MHz, respectively). This anomaly could be 
due to sample history. 
Figure 5.7 shows two distinctive changes in slope through the studied range of 
temperature. The first change occurs around Tg, at around 45°C, which indicates a 
increase in mobility, as expected. The second change, which appears to involve a 
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minimum, happens at around 80°C and could be caused by the start of the 
recrystallisation. However, if recrystallisation occurs then it is expected that the 
value of T1H would begin to increase, which is not seen in figure 5.6. This is 
consistent with what was observed by 13C VT SSNMR in chapter Four; that is to say 
that this change could be due to an increased molecular mobility. One can also see 
that below Tg the slope of T1pH is slightly negative while that for T1H is positive, 
clearly showing a difference in the motion process monitored by the two relaxations, 
which is expected and explained in chapter Three. 
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Figure 5.7: T1pH measurements for amorphous indomethacin. The change of slope is 
observed at Tg (45°C). 
As for the T1H study, it is possible to see that the relaxation times are lower for the 
amorphous phase, even though they are complicated by the minimum for the 
crystalline form. This suggests that amorphisation increases the mobility of the 
sample, as expected. 
1.2.2) Nifedipine 
The firSt experiments done on amorphous nifedipine showed a rather abnormal, and 
irreproducible, jump in T1H at around 20°C (data not shown). As stated in chapter 
Two, one needs to be careful when dealing with temperature-dependent 
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measurements as the temperature inside the probe rises quite quickly in order to 
compensate when the VT controller is switched off. As amorphous nifedipine 
involved temperature-dependent NMR properties, this explains the phenomenon 
observed which was solved by following the protocol described in chapter Two. 
Figure 5.8 shows the T1H curve, as a function of the temperature, obtained for 
amorphous nifedipine. The raw data are given in appendix 21 . 
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Figure 5.8: T 1 H measurements for amorphous nifedipine. The maximum is observed 
to be at ca. 40°C. 
From figure 5.8, it can be seen that a maximum is observed to be at ca. 40°C which 
is significantly lower than Tg (measured to be 46°C using DSC, see figure 4.9). This 
maximum indicates a change in mobility happening before Tg; this could be a reason 
why amorphous nifedipine is not as stable as amorphous indomethacin. 
When comparing the crystalline and amorphous relaxation times data, one can see 
that, as for indomethacin, the T 1 H slopes run parallel until Tg. Furthermore, the 
crystalline T 1 H values are higher than for the amorphous, showing more mobility for 
the amorphous material, as for indomethacin. However, the difference observed 
between the two phases of the sample for nifedipine is larger than for indomethacin, 
perhaps also helping to explain the tendency of nifedipine to recrystallise. 
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Figure 5.9 shows the T1/ curve, as a function of the temperature, obtained for 
amorphous nifedipine. The raw data are given in appendix 22. 
From this figure it is again visible that a change in the slope happens at a temperature 
5-8°C lower than Tg, which is in agreement with what was observed for T1H and also 
with the work of Aso et al. 4 . This confirms that there is something happening to 
amorphous nifedipine before it reaches Tg. However, it is not possible to determine 
what is exactly happening, though one could say that this is probably related to the 
lack of stability for amorphous nifedipine. 
5 4.5 4 3.5 3 2.5 
Figure 5.9: TIp H measurements for amorphous nifedipine. The change in slope is 
observed at ca. 40°C. 
As for indomethacin, the TIp H values for amorphous nifedipine are smaller than for 
the crystalline counterpart, though in this case, T 1p11 is too long for the crystalline 
material to be measured. Clearly, the difference in T1rH values between the two 
phases is far greater for nifedipine than for indomethacin, as was observed for T 1 H_ 
This supports the idea that the amorphisation of the sample makes it more mobile. 
Furthermore, the larger difference in TIp H values indicates that nifedipine is 
relatively more mobile than indomethacin, which could explain why nifedipine has a 
greater tendency to recrystallise than indomethacin. 
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1.2.3) Carbamazepine 
Figure 5.10 shows the T1H curve, as a function of temperature, obtained for 
amorphous carbamazepine. The raw data is given in appendix 23 . 
From this figure it can be seen that a maximum appears at ca. 55°C, which is close to 
Tg (Tg was found to be 57°C for amorphous carbamazepine, see figure 4.14). This 
maximum appears to be the recovery of the system after a minimum that seems to be 
around -30°C. This minimum is broad and shallow, as would be expected for an 
amorphous system (see the discussion at the beginning of part 1.2). 
In chapter Three, it was noted that no information could be retrieved from the T 1 H 
measurements on crystalline carbamazepine. This was linked to the lack of 
conformational flexibility of the molecule. Moreover, if one compares the crystalline 
and amorphous T 1 H behaviour over this range of temperature, it is clearly visible that 
the T1H values are lower for the amorphous form than for the crystalline form. This 
demonstrate that amorphisation is making carbamazepine, as for the other two 
samples, somewhat more mobile. 
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Figure 5.10: T1H measurements for amorphous carbamazepine. A maximum IS 
observed at ca. 55°C. 
From figure 5.6 and figure 5.10, one can see that amorphous indomethacin and 
amorphous carbamazepine are quite similar in their behaviour, that is to say that they 
both go through a maximum around their Tg and also that they appear to go through 
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a broad minimum at low temperature. If one also considers figure S.8, it is visible 
that amorphous nifedipine is different from the other two drugs because the 
maximum happens before Tg. This is probably a reason for the poor stability of 
amorphous nifedipine. One could suggest from the similarity between indomethacin 
and carbamazepine that carbamazepine is stable when amorphous. However, as seen 
earlier, the big difference in T 1 H values from crystalline to amorphous for 
carbamazepine seems to point to a relatively unstable amorphous material, as 
observed experimentally. 
Figure S.ll shows the T1pH curve, as a function of temperature, obtained for 
amorphous carbamazepine. The raw data is given in appendix 23 . 
From this figure, a visible change in slope happens between 3S°C and 4S°C, t.e. 
before Tg. This change in slope shows that something happens to the motional 
process of the molecule which could be causing some disturbances, and as such may 
be related to the lower stability of amorphous carbamazepine. 
From figure S.ll, it can be observed that the T1/ curve goes through a minimum 
between 7S°C and 8S°C. This change in the value ofT tpH is probably due to the 
recrystallisation of the material. This was confirmed by the proton bandshapes study 
where it was visible, see figure S.S, that the recrystallisation probably starts between 
7S°C and ssoc. 
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Figure 5.11: Tt/ measurements for amorphous carbamazepine. A change in slope is 
observed between 3S°C and 45°C and a minimum between 75°C and 85°C. 
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As for the other two compounds, the T1/ values for amorphous carbamazepine are 
smaller than for the crystalline counterpart; the T1pH values being too long for the 
crystalline material to be measured. Much as for nifedipine, the difference in T1pH 
values between the two phases is clearly far greater for carbamazepine than for 
indomethacin. This strengthens the fact that the amorphisation of the sample makes it 
more mobile, but also that amorphisation gives carbamazepine a greater tendency to 
recrystallise than indomethacin. 
When comparing figure 5.7, figure 5.9 and figure 5.11, one can see that all three 
compounds go through a change in slope around or before Tg. It was also seen that 
indomethacin and carbamazepine go through a minimum at high temperature. 
However, this minimum may be caused by an increase in molecular mobility for 
indomethacin while it might be caused by recrystallisation for carbamazepine . It was 
observed through these three figures that a change in slope before Tg' could possibly 
be linked to a compound being more prone to recrystallisation. 
2/ Conclusions 
2.1/ Proton bandshape 
It has been seen that indomethacin recrystallises above 1 oooc in the time scale of the 
SSNMR experiments. 
In the case of nifedipine, the recrystallisation process started at around 70°C and a 
two-phase system seemed to be present during this recrystallisation. This could 
explain what was observed with the DSC and hot-stage microscopy experiments. 
For carbamazepine, the recrystallisation process may have started around 75°C, 
although this is not clear. However, due to the long pulse delay necessary for 
amorphous carbamazepine, information at higher temperatures than 1 05°C using the 
pulse-and-acquire pulse sequence could not be obtained. 
2.2/ T1H and T1pH measurements 
It was seen from the T1H experiments on the three amorphous samples that the 
amorphisation process seemed to increase the mobility of the sample. However, this 
increase in mobility was larger for carbamazepine and nifedipine than for 
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indomethacin. This could possibly explain the fact that the two former samples are 
more prone to recrystallisation than the latter. It was also seen that indomethacin and 
carbamazepine behave similarly as they both show a change in slope around Tg. 
Although this seemed to indicate that amorphous carbamazepine, like amorphous 
indomethacin, is relatively stable, the change in T 1 H value from crystalline to 
amorphous seems to indicate the opposite, which is consistent with the experimental 
data. This difference seemed to show that one should look at the results from both 
phases, not just from the amorphous material, in order to understand the stability of 
the amorphous phase. 
The results obtained from the T1/ experiments seemed to confirm that 
amorphisation increases the mobility of the sample. These experiments also showed 
that all three compounds go through a change in slope. This change in slope 
happened around Tg for indomethacin and before Tg for the other two compounds 
and it seemed that a change in slope before Tg could be linked to a compound being 
more prone to recrystallisation. It was also seen that indomethacin and 
carbamazepine go through a minimum at high temperature. However, this minimum 
seemed to be caused by a different phenomenon for each compound, i.e. increased 
molecular mobility for indomethacin and recrystallisation for carbamazepine. 
Therefore, the presence of a minimum is not particularly indicative of any particular 
phenomenon and should be investigated using other experiments, such as 
13C SSNMR and XRPD. 
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· 11 Results 
This chapter will look at the results obtained on the PVP/drug co-melts using 13C and 
1H SSNMR. This will involve studying the 13C spectra of the co-melts in order to 
check their amorphous character. This will also involve the study of the proton 
bandshapes as a function of temperature in order to obtain information about the 
effect of PVP on the system. It will also involve looking at the T1H and T1p H values 
obtained over a wide range of temperatures in order to gain some information on the 
effect of PVP on the motional processes. 
1.1/ PVP 
Amorphous drugs in formulation are often associated with a polymeric compound 
acting as an antiplasticiser. In the case of this study, PVP was used because it has a 
high Tg when dry, i.e. 165°C. However, this polymer is really hygroscopic, which 
implies that its' Tg will decrease rapidly in the presence of humidity. Nevertheless, 
the mix of the amorphous drug and such a polymer will have a higher Tg than the 
amorphous drug itself. Therefore, the formulation will probably have a greater 
stability than the amorphous drug alone. In order to minimise the amount of moisture 
going into the sample, a sufficient portion of PVP was dried under vacuum for a 
minimum of 3 hours before every experiment. Moreover, the drug and PVP portions 
were weighed quickly after the removal of the PVP sample from the oven and put 
straight into the oven in order to obtain the co-melt 
The CPMAS 13C SSNMR spectrum of PVP itself was acquired and is shown in 
figure 6.1. The assignment of PVP is the work of Zheng et al. 1 
Figure 6.2 shows the proton bandshapes obtained from the last spectrum of the Tt 
array at different temperatures for PVP. The timing for the experiment is shown in 
table 6.1. This figure shows that two components are present from the beginning of 
the experiment and also that the intensity in the narrow signal starts to be lost at 80°C 
and has practicatty gone by 90°C. 
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Chemical shift /ppm Atom number 
18.7 3 
31.8 4 
::::36 7 
43.2 2 and6 
174.4 5 
200 180 160 140 120 100 80 60 40 20 0 
o/ppm 
Figure 6.1: Be CPMAS spectra ofPVP obtained at 50.32 MHz, Be frequency. The 
asterisk shows the spinning sideband. 
100 50 0 
kHz 
-50 -100 
Figure 6.2: Proton bandshapes obtained from the last spectrum of the T1H array at 
different temperatures for pyp2_ Bottom to top, the temperature values are -20, 20, 
80, 90, 100 and 140°C. 
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The study of T1H and T 1/ of quench-cooled PVP over a range of temperature was 
done by Dr. D.C. Apperley using a 300 MHz spectromete~. The results obtained are 
shown in figure 6.3 and figure 6.4, with the raw data given in appendix 24. The 
timing for this experiment is shown in table 6.1. 
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Figure 6.3: T1H measurements for quench-cooled PVP. 
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Figure 6.4: T1pH measurements for quench-cooled PVP. 
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Temperature I Temperature reached Experiment started Experiment finished 
oc at I hr:min at I hr:min at I hr:min 
-20 0:00 0:12 0:35 
-10 0:40 0:43 1:02 
0 1:07 1:10 1:23 
10 1:28 1:31 1:42 
20 1:47 1:51 2:02 
30 2:07 2:16 2:27 
40 2:32 2:43 2:52 
50 2:57 3:02 3:15 
60 3:20 3:29 3:40 
70 3:45 3:50 4:01 
80 4:06 4:I5 4:28 
90 4:33 4:57 5:17 
100 5:22 5:31 5:55 
110 6:00 6:I4 6:37 
120 6:42 6:56 7:22 
130 7:27 7:36 7:59 
I40 8:04 8:20 8:48 
Table 6.1: Timing used for the T1H and T1/ experiments performed on pure PVP. 
The experiment times include both experiments. 
These experiments are important as they help in determining if the T1H and T1/ 
measurements of the PVPidrug co-melts are dominated by the behaviour ofPVP. 
The mixtures prior to being melted are physical mixtures with a I: I ratio in mass; 
this corresponds to a percentage of hydrogen atoms, from the drug, in the mixture of 
35.6%, 39.I% and 38.6%, for PVPiindomethacin, PVPinifedipine and 
PVPicarbamazepine co-melts respectively. The co-melts were obtained using the 
protocol shown in chapter Two. In order to check the amorphous character of the 
PVPidrug co-melts, a 13C CPMAS SSNMR spectrum was obtained and compared to 
those of the crystalline and amorphous forms of the drug on their own. 
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1.2.1) PVP/indomethacin 
The 13C CPMAS SSNMR spectra of crystalline and amorphous indomethacin, and of 
the PVP/drug co-melt are shown in figure 6.5. The spectrum of PVP on its own is 
shown for reference. 
- Crystalline 
- Amorphous 
- PVP/drug comelt 
- PVP 
200 180 160 140 120 100 80 60 40 20 0 
8 /ppm 
Figure 6.5: 13C CPMAS SSNMR spectra of crystalline and amorphous 
indomethacin, PVP/indomethacin co-melt and PVP alone obtained at 50.32 MHz, 
13C frequency. 
One can see from figure 6.5 that the peaks, not overlapped by PVP peaks, of the 
PVP/drug co-melt are really similar to those of the amorphous indomethacin, but not 
as well defined as for the crystalline case. This shows that the PVP/drug co-melt is 
actually amorphous. The differences in chemical shifts between the pure amorphous 
drug and the PVP/drug co-melt are shown in table 6.2. It is important to consider the 
likely errors occurring when obtaining these chemical shifts: there could be a 
difference in the referencing from one experiment to the other, or the peak peaking 
could be not exactly at the centre of the peaks. 
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200MHz 300 MHz2 
Chemical shift I ~pm Chemical shift I ~pm 
Amol]>_hous Co-melt Difference Amorphous Co-melt Difference 
55.1 55.2 -0.1 54.8 54.9 -0.1 
113.1 113.9 -0.8 113.9 114.1 -0.2 
130.7 131.1 -0.4 130.9 131.6 -0.7 
156.0 156.1 -0.1 156.4 156.6 -0.2 
Table 6.2: Differences of chemical shifts between the pure amorphous form and the 
co-melt for indomethacin. 
From table 6.2 it can be seen that the chemical shifts of the pure amorphous drug and 
the one of the co-melt are similar, and, as such, do not provide any evidence of any 
strong specific chemical interactions between the two compounds. This is consistent 
with the work of Taylor and Zografi3• This similarity was observed at two magnetic 
fields. Note that all the calculated differences are negative, which could arise from 
instrumental effects or non-specific interactions. 
1.2.2) PVP/nifedipine 
The 13C CPMAS SSNMR spectra of crystalline and amorphous nifedipine, and ofthe 
PVPidrug co-melt are shown in figure 6.6. The spectrum of PVP on its own is shown 
for reference. 
200 MHz 300 MHz2 
Chemical shift I )pm Chemical shift I )pm 
Amorphous Co-melt Difference Amorphous Co-melt Difference 
50.8 50.4 0.4 51.1 50.7 0.4 
103.1 102.9 0.2 124.2 124.0 0.2 
132.1 131.7 0.4 126.8 127.0 -0.2 
147.9 147.8 0.1 132.3 132.0 0.3 
167.4 167.5 -0.1 147.0 147.0 0.0 
Table 6.3: Differences of chemical shifts between the pure amorphous form and the 
co-melt for nifedipine. 
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As for indomethacin, it can be seen that the PVP/drug mixture is amorphous by 
comparing its spectrum to that of the crystalline and amorphous drugs. The 
differences in chemical shifts between the pure amorphous drug and the PVP/drug 
co-melt are shown in table 6.3. 
- Crystalline 
- Amorphous 
- PVP/drug comelt 
- PVP 
200 180 160 140 120 100 80 60 40 20 0 
8/ppm 
Figure 6.6: 13C CPMAS SSNMR spectra of crystalline and amorphous nifedipine, 
PVP/nifedipine co-melt and PVP alone obtained at 50.32 MHz, 13C frequency . 
From table 6.3 it can be seen that the chemical shifts of the pure amorphous drug and 
the one of the co-melt are similar and as such do not provide any evidence of any 
strong specific chemical interactions between the two compounds. This similarity 
was observed at two magnetic fields. 
1.2.3) PVP/carbamazepine 
The 13C CPMAS SSNMR spectra of crystalline and amorphous carbamazepine, and 
ofthe PVP/drug co-melt are shown in figure 6.7. The spectrum ofPVP on its own is 
shown for reference. As for indomethacin and nifedipine, it is visible that the 
PVP/drug mixture is amorphous by comparing its spectrum to that of the crystalline 
and amorphous drugs. The differences in chemical shifts between the pure 
amorphous drug and the PVP/drug co-melt are shown in table 6.4. 
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- CrystaUine 
- Amorphous 
- PVP/drug comelt 
PVP 
200 180 160 140 120 100 80 60 40 20 0 
o /ppm 
Figure 6.7: 13C CPMAS SSNMR spectra of crystalline and amorphous 
carbamazepine, PVP/carbamazepine co-melt and PVP alone obtained at 50.32 MHz, 
13C frequency. 
200MHz 
Chemical shift I Jpm 
Amorphous Co-melt Difference 
129.2 129.4 -0.2 
134.4 134.7 -0.3 
140.4 140.7 -0.3 
158.0 157.2 0.8 
Table 6.4: Differences of chemical shifts between the pure amorphous form and the 
co-melt for carbamazepine. 
Table 6.4 shows that there are no significant differences between the chemical shifts 
obtained for the pure amorphous drug and those of the co-melt. This seems to show 
that there is no strong chemical interactions between the two components of the co-
melt. 
1.3/ Proton bandshapes 
The proton bandshapes of PVP2 and of the PVP/drug co-melts were recovered, as 
secondary information, from the T1H and T1pH experiments, more precisely from the 
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last spectrum of the array for T1H and the first spectrum of the array for T1pH, as 
stated in chapter Five. They were then analysed in order to get some information on 
the way the samples behaved over a wide range of temperatures. This helps to 
understand the effect on mobility caused by the addition of a polymer to the system. 
As for chapter Five, only the proton band shapes obtained from the T 1 H are shown 
since the T 1 H and T lp H experiments, as expected, yielded similar spectra. 
1.3 .1) PVP/indomethacin 
Figure 6.8 shows the proton bandshapes obtained from the last spectrum ofthe T1H 
array at different temperatures for the PVP/indomethacin co-melt. The timing for the 
experiment is shown in table 6.5. The timing was matched to within two hours 
between the different series of experiments studied. 
When comparing the proton bandshapes of PVP and of the PVP/indomethacin 
co-melt, one can see that PVP does not seem to have influence on the co-melt. 
300 250 200 !50 100 
kHz 
50 
- 140°C 
- 120°C 
- )l0°C 
- 100°C 
- ssoc 
- 65°C 
- 40°C 
- l5°C 
- -!Ooc 
- -40°C 
- -70°C 
0 -50 -100 
Figure 6.8: Proton bandshapes obtained from the last spectrum of the T 1 H array at 
different temperatures for the PVP/indomethacin co-melt. The horizontal scale is for 
reference only. 
If one looks at figure 6.8, it can be seen that there is no real change, apart from a 
slight sharpening, in the proton bandshape for temperatures between -70°C and 
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65°C. However, at 85°C the sharpening seems to be more pronounced and this is 
definite from 1 00°C. At the same time, the broad underlying peak seems to be 
decreasing. This shows that that there is an increase in mobility which is probably 
due to the co-melt going through a transition related to the Tg of the co-melt. It 
should be noted that when two compounds are mixed at a molecular level, the Tg of 
the mixture should be the average of the Tg of the separate components. It is then 
possible to calculate the theoretical Tg of PVP/indomethacin co-melt to be at 105°C. 
The fact that the transition happens at a lower temperature may indicate that the PVP 
sample was not totally dry, and, as such, its' Tg would have been lower due to the 
plasticising effect of water. 
Tern perature I Temperature reached Experiment started Experiment finished 
oc at I hr:min at I hr:min at I hr:min 
-70 0:00 0:20 0:34 
-40 0:39 0:59 I: 15 
-10 1:20 1:40 1:57 
15 2:02 2:22 2:42 
40 2:47 3:07 3:31 
65 3:36 3:56 4:23 
85 4:28 4:48 5:14 
100 5:19 5:39 6:07 
110 6:12 6:22 6:49 
120 6:54 7:04 7:28 
140 7:33 7:53 8:14 
Table 6.5: Timing used for the T1H and T1/ experiments performed on the 
PVPiindomethacin co-melt. The experiment times include both experiments. 
1.3.2) PVP/nifedipine 
Figure 6.9 shows the proton bandshapes obtained from the last spectrum of the T1H 
array at different temperatures for the PVPinifedipine co-melt. The timing for the TtH 
and T1pH experiments is shown in table 6.6. This timing was matched to within two 
hours between the different series of experiments. 
The proton bandshapes obtained for the PVPinifedipine co-melt, figure 6.9, show a 
very similar behaviour to those obtained for the PVPiindomethacin co-melt, figure 
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6.8. Therefore, it is possible to say that a change of mobility is happening at some 
point between 65°C and 1 00°C and that this change in mobility is probably due to a 
the PVPinifedipine co-melt going through its Tg. 
300 250 200 150 100 
kHz 
50 
- 140°C 
- 120°C 
- uooc 
- l00°C 
- 85°C 
- 65°C 
- 40°C 
- 0°C 
- -40°C 
- -70°C 
0 -50 -100 
Figure 6.9: Proton bandshapes obtained from the last spectrum of the T 1 H array at 
different temperatures for the PVPinifedipine co-melt. The horizontal scale is for 
reference only. 
Temperature I Temperature reached Experiment started Experiment finished 
oc at I hr:min · at I hr:min at I hr:min 
-70 0:00 0:20 0:38 
-40 0:43 1:03 1:21 
0 1:26 1:46 2:04 
40 2:09 2:29 2:51 
65 2:56 3:16 3:42 
85 3:47 4:07 4:33 
100 4:38 4:58 5:25 
llO 5:30 5:40 6:05 
120 6:10 6:20 6:44 
140 6:49 7:19 7:39 
. ti ti Table 6.6. Ttmmg used for the T1 and T1p expenments performed on the 
PVPinifedipine co-melt. The experiment times include both experiments. 
The comparison between the proton bandshapes of PVP and the PVPinifedipine co-
melt seems to indicate that PVP does not influence strongly the co-melt. 
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1.3.3) PVP/carbamazepine 
Figure 6.10 shows the proton bandshapes obtained from the last spectrum ofthe T1" 
array at different temperatures for the PVP/carbamazepine co-melt. The timing for 
the experiment is shown in table 6.7. The timing was matched to within two hours 
between the different series of experiments. 
300 250 200 150 100 
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50 
- 140°C 
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- -70°C 
0 -50 -100 
Figure 6.10: Proton bandshapes obtained from the last spectrum ofthe T1" array at 
different temperatures for the PVP/carbamazepine co-melt. The horizontal scale is 
for reference only. 
The proton bandshapes shown in figure 6.10 seem to be composed of a peak 
surrounded by two "wings". This is very similar to what was observed for the pure 
amorphous drug. However, the main peak is not centred as was the case for the pure 
amorphous system; this could be due to the presence ofPVP in the co-melt. 
The same conclusion as for the other two co-melts can been drawn from these 
bandshapes; that is to say that a change of mobility is observed, which is probably 
due to the Tg of the co-melt. However, in this case it is easier to pinpoint the 
temperature at which the mobility seems to change which occurs between 85°C and 
100°C. It can also been seen, by comparing figure 6.2 and figure 6.10, that PVP does 
not seem to have much influence in the behaviour ofthe PVP/carbamazepine co-melt. 
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Temperature I Temperature reached Experiment started Experiment finished 
oc at I hr:min at I hr:min at I hr:min 
-70 0:00 0:20 0:46 
-30 0:51 1:11 1:36 
10 I :41 2:01 2:25 
40 2:30 2:50 3:16 
65 3:21 3:41 4:14 
85 4:19 4:39 5:11 
100 5:16 5:36 6:07 
110 6:12 6:22 6:50 
120 6:55 7:05 7:31 
140 7:36 7:56 8:16 
Table 6.7: Timing used for the T1H and T1/ experiments performed on the 
PVPicarbamazepine co-melt. The experiment times include both experiments. 
The measurements have been carried out at least in duplicate using the PVPidrug 
co-melt samples which were prepared according to the protocol shown in chapter 
Two. 
As the co-melts are mixtures of a polymer and an amorphous drug, the statement on 
activation energies applies in this case, i.e. it would be meaningless to retrieve 
activation energies from the slope of the T1H and T1pH experiments. Furthermore, the 
presence of the polymer in the mixture will complicate the phenomenon and it would 
be equally meaningless to relate the measurements to barriers to rotation. It is also 
important to note that the relaxation times of the co-melts measure an average for the 
drug and PVP. If the PVPidrug mixing occurs essentially at the molecular level, as 
expected from the co-melting procedure, spin diffusion should be efficient between 
the components. 
1.4.1) PVP/indomethacin 
Figure 6.11 shows the T1H curve, as a function of the temperature, obtained for the 
PVPiindomethacin co-melt. The raw data are given in appendix 25. Figure 6.12 
shows the comparison of the T1H curves, as a function of temperature, of the 
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crystalline form, the pure amorphous drug, the PVP/drug co-melt and pure PVP (note 
that only one set of measurements is shown for simplicity). 
From figure 6.11, it can be seen that the mixture appears to behave somewhat 
differently at different magnetic fields. It actually seems that the data acquired at a 
proton frequency of 300 MHz are relatively erratic compared to that obtained at 
200 MHz. Comparison between figure 6.3 and figure 6.11 shows that the erratic 
character of the measurements observed at 300 MHz could be due to the presence of 
PVP. However, the presence of the polymer does not seem to influence the T1H 
measured at 200 MHz, see figure 6.12. 
3 
I l gsoc 1140°C -70°C Jooc I Tg of 
amorphous I 
2.5 indomethacin 
• 300MHz 
2 • 200MHz ••• 
.--.. 
A200MHz • • • 
Vl t • *•• 
-- • ;r: ~1.5 A 
• ......... •• • .s 
• • • • 
' I • A 
0.5 
r 0 
4.7 4.2 3.7 3.2 2.7 2.2 
103/T /K 
Figure 6.11: T1H measurements for the PVP/indomethacin co-melt. 
One can see from figure 6.11 that a definite maximum is visible well above the Tg of 
amorphous indomethacin, which seems to show that the sample is less prone to 
changes until higher temperatures. Therefore, the co-melt seems to be more stable, as 
expected due to the presence of the polymer. The maximum observed from the 200 
MHz data is at ca. 85°C, whilst it is at ca. 110°C from the 300 MHz data. The 
maximum for the 200 MHz data appears after a steady increase in the T 1 H value from 
-70°C which could indicate recovery from a T 1 H minimum at or below -70°C. The 
difference in the temperature at which the maximum is observed between the two 
magnetic fields could be due to the amount of water present in the sample; it has 
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been said that water was a plasticiser and, as such, could influence the value of Tg. 
As a consequence, it could be assumed that the transition observed at 85°C is 
probably due to the Tg of the co-melt. 
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Figure 6.12: Comparison of the T 1 H curves obtained for crystalline and amorphous 
indomethacin, PVP/indomethacin co-melt and pure PVP2. 
If one compares the slopes obtained form the crystalline and amorphous materials to 
those obtained from the co-melt, see figure 6.12, it can be seen that the co-melt has a 
smaller slope than the other two states of the sample. It is also noticeable that the T1H 
value is slightly higher for the co-melt than for the other states when observing 
below 1 0°C, but this value is changing to become between the values of the other 
states above this temperature. This shows that the co-melt is more rigid than the other 
states below 10°C. However, this somehow changes past this temperature as the co-
melt seems to be more mobile than the crystalline material, but more rigid than the 
amorphous sample. This seems to reinforce the statement of the previous chapter 
which suggested that amorphisation increases molecular mobility, whilst the higher 
maximum value seems to show that the co-melt is somewhat more stable that the 
amorphous drug on its own. 
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Figure 6.13 shows the T 1/ curve, as a function of temperature, obtained for the 
PVP/indomethacin co-melt. The raw data is given in appendix 25. 
This figure shows similar behaviour between the two different magnetic fields with a 
small, but consistent, difference in the magnitude ofT lpH which was expected as B1 
was set to 70 kHz and 50 kHz for the 300 MHz and 200 MHz spectrometers, 
respectively. It is visible that, for both magnetic fields, the slopes change at ca. 85°C, 
and that the data from the 300 MHz spectrometer shows a broad shallow minimum at 
ca. 130°C which is not present within the data from the 200 MHz spectrometer. 
Figure 6.14 shows the comparison of the T 1/ curves, as a function of temperature, of 
the crystalline form, the pure amorphous drug, the PVP/drug co-melt and pure PVP 
(note that only one set of measurements is shown for simplicity). 
If one compares the data obtained for the amorphous sample to those from the co-
melt, one can see that they have a very similar slopes and T1pH values below Tg, see 
figure 6.14. However, the change of slope occurs around Tg for the amorphous 
sample, whilst it occurs around 85°C for the co-melt, and this change in slope is 
probably due to Tg. This seems to indicate that the co-melt is more stable than the 
amorphous material. As stated in the previous chapter, it is possible to see that the 
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relaxation times are lower for the amorphous phase than for crystalline 
indomethacin, even though complicated by the minimum for the crystalline form. 
Furthermore, as both the co-melt and amorphous states have similar values of T lp H 
this conclusion also holds for the co-melt, indicating a more mobile state than that of 
the crystalline material. This, again, suggests that amorphisation leads to a more 
mobile system. 
Tg l 
I 
I 
I • 
• 
• • • • • • I • 
• •• • • • • •• • 
• • • •• • 
• • • • 
• • • 
• 
• 
• 
0 • • • 
-1 ~----,---------.---------,----------r---------.--------~ 
4.7 4.2 3.7 3.2 2.7 2.2 
103ff I K 
Figure 6.14: Comparison ofthe T1pH curves obtained for crystalline and amorphous 
indomethacin, PVP/indomethacin co-melt and pure PVP. 
Figure 6.14 seems to indicate that the relaxation of PVP is not dominating the 
relaxation of the co-melt. However, the T 1/ curves for both PVP and 
PVP/indomethacin co-melt go through a transition at 85°C, this transition seems to 
be due to the Tg of the co-melt for the latter but is not explainable for PVP. 
1.4.2) PVP/nifedipine 
Figure 6.15 shows the T 1 H curve, as a function of temperature, obtained for the 
PVP/nifedipine co-melt. The raw data are given in appendix 26. 
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Figure 6.16 shows the comparison ofthe T1H curves, as a function oftemperature, of 
the crystalline form, the pure amorphous drug, the PVP/drug co-melt and pure PVP 
(note that only one set of measurements is shown for simplicity). 
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Figure 6.15: T 1 H measurements for the PVP/nifedipine co-melt. 
As for the PVP/indomethacin co-melt, it is visible, from figure 6.15, that the data 
obtained at a proton frequency of300 MHz are more erratic than the ones obtained at 
a proton frequency of 200 MHz; this could be due to the presence of PVP. This 
figure also shows that for both magnetic fields a maximum is reached at a 
temperature above the Tg of the amorphous drug on its own, i.e. at ca. 85°C with the 
200 MHz data and at ca. 120°C with the 300 MHz data. This leads to the same 
conclusion as for the PVP/indomethacin co-melt; that is to say that the co-melt seems 
more stable than the amorphous drug on its own. The maximum observed from the 
200 MHz data appears to be coming from the recovery of a shallow T 1 H minimum 
happening between -40°C and -30°C. The higher temperature observed for the 
maximum for the co-melt compared to that for the amorphous drug seems to indicate 
that the co-melt is more stable that the amorphous drug on its own, as observed in the 
case of indomethacin. The difference in the temperature when the maximum is 
observed is probably due to a difference in water content between the two samples; 
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thus confirming that the transition observed at 85°C at 200 MHz is due to the Tg of 
the co-melt. 
If one compares the slopes obtained form the crystalline and amorphous materials to 
the ones obtained from the co-melt (figure 6.16), it is visible that all three states have 
similar slopes until Tg. It is also noticeable that the co-melt T 1 H value are the 
smallest of those for the three states, showing that the co-melt is more mobile than 
the crystalline or amorphous materials. This again seems to reinforce the statement of 
the previous chapter, which suggested that amorphisation increased molecular 
mobility. 
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Figure 6.16: Comparison ofthe T1H curves obtained for crystalline and amorphous 
nifedipine, PVP/nifedipine co-melt and pure PVP2. 
When comparing figure 6.11 and figure 6.15, it is visible that both co-melts go 
through a maximum in T1H value at around 85°C. However, the PVP/nifedipine co-
melt also shows a possible minimum at around -30°C, whilst this minimum seems to 
be at a lower temperature for indomethacin. Nevertheless, both co-melts seem to be 
more stable than their respective amorphous form. 
Figure 6.17 shows the T1pH curve, as a function of temperature, obtained for the 
PVP/nifedipine co-melt. The raw data is given in appendix 26. 
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Figure 6.17 shows a very similar behaviour to that which was observed for 
indomethacin, see figure 6.13; that is to say that a slight difference is observed in the 
values ofT lp 8 between the different magnetic fields and that a shallow minimum is 
observed from the 300 MHz data and not from the 200 MHz data. However, in this 
case the slopes behave differently between the two magnetic fields as the slope 
changes at a lower temperature when considering the 300 MHz data, at ca. 50°C, 
compared to the 200 MHz data, at ca. 65°C. Nevertheless, in both cases, this change 
in slope is occurring at a higher temperature than for the amorphous drug on its own, 
which again seems to indicate that the co-melt is somewhat more stable that the 
amorphous material. 
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Figure 6.17: T tp 8 measurements for the PVP/nifedipine co-melt. 
Figure 6.18 shows the comparison ofthe T1p8 curves, as a function oftemperature, of 
the pure amorphous drug, the PVP/drug co-melt and pure PVP (note that only one set 
of measurements is shown for simplicity). 
If one compares the data obtained for the amorphous sample to the ones from the co-
melt, see figure 6.18, one can see that they have very similar slopes and T lp 8 values, 
up to the change of slope. This change of slope is observed for the amorphous 
sample at ca. 40°C, which is at a lower temperature than for the co-melt, as stated 
previously. It was shown in the previous chapter that the T1p8 values were not 
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obtained for the crystalline material as they were too long to be measured. Therefore, 
the amorphous and co-melt have smaller TIp H values than the crystalline material 
and, as such, are probably more mobile. This strengthens again the fact that 
amorphisation seems to render the sample more mobile and that the presence of PVP 
make a more stable sample than the amorphous drug on its own. 
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Figure 6.18: Comparison of the T1pH curves obtained for amorphous nifedipine, 
PVP/nifedipine co-melt and pure PVP. 
The comparison of figure 6.4 and figure 6.17 seems to indicate that the relaxation of 
PVP is not dominating the relaxation of the co-melt. 
As observed for indomethacin and in the previous chapter, the slopes obtained with 
the T lp H data are negative below the change of slopes, whilst they are positive for 
T1H. Furthermore, this change of slope happens at a lower temperature for T1pH than 
for T1H· These two points clearly show a difference in the motional process, which is 
expected, as explained in chapter Three. 
Figure 6.13 and figure 6.17 show that the T1pH values for those two co-melts behave 
in a similar way and follow similar slopes apart from the fact that PVP/nifedipine 
goes through a change of slope at a lower temperature than PVP/indomethacin, when 
looking at the 300 MHz data. This could indicate a less stable sample. However, both 
co-melts seem to be more stable than their amorphous counterparts. 
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1.4.3) PVP/carbamazepine 
Figure 6.19 shows the T 1 H curve, as a function of temperature, obtained for the 
PVP/carbamazepine co-melt. The raw data is given in appendix 27. 
Figure 6.19 shows that a maximum happens at ca. 85°C and that this maximum 
appears to be the recovery of the system after a minimum that seems to occur around 
-30°C. It is also visible that this maximum happens at a temperature above the Tg of 
the amorphous drug on its own, which probably indicates a more stable system. 
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Figure 6.19: T1H measurements for the PVP/carbamazepine co-melt. 
Figure 6.20 shows the comparison ofthe T 1H curves, as a function oftemperature, of 
the pure amorphous drug, the PVP/drug co-melt and pure PVP (note that only one set 
of measurements is shown for simplicity). 
When comparing the T1H values obtained from the different states, i.e. co-melt, 
amorphous and crystalline (see figure 6.20), one can see that the ones for the 
amorphous and the co-melt systems are lower than those for the crystalline system. 
This probably shows that the amorphous and co-melt systems are more mobile than 
their crystalline counterpart. It is also possible to see that up to Tg the T 1 H values are 
slightly higher for the amorphous drug than for the co-melt, and that their slopes are 
similar up to this temperature. Moreover, as said earlier, the maximum in T 1 H 
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happens at a higher temperature for the co-melt. This seems to show that the co-melt 
is more stable and slightly more mobile than the amorphous drug. 
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Figure 6.20: Comparison of the T 1 H curves obtained for crystalline and amorphous 
carbamazepine, PVP/carbamazepine co-melt and pure PVP2. 
The companson between figure 6. 19, figure 6. 11 and figure 6. 15 shows that 
PVP/carbamazepine behaves in a similar way to the other two co-melts, having a 
maximum at around 85°C. This co-melt also shows a minimum in T1H around -30°C, 
which is similar to what was observed for PVP/nifedipine. As for the other co-melts, 
PVP/carbamazepine seems to be more stable than amorphous carbamazepine without 
PVP, and it also seems that the relaxation ofPVP is not dominating the relaxation of 
the co-melt. 
Figure 6.21 shows the T lp H curve, as a function of temperature, obtained for the 
PVP/carbamazepine co-melt. The raw data is given in appendix 27. 
From this figure, it can be seen that a change in slope happens around 85°C. This is 
similar to what is seen with the T 1 H values. However, this change happening at the 
same temperature for both T 1 and T lp is probably fortuitous as these properties are 
dependent on different parameters. 
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Figure 6.21: T1pH measurements for the PVP/carbamazepine co-melt. 
Figure 6.22 shows the comparison ofthe T1H curves, as a function oftemperature, of 
the pure amorphous drug, the PVP/drug co-melt and pure PVP (note that only one set 
of measurements is shown for simplicity). 
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Figure 6.22: Comparison ofthe T1pH curves obtained for amorphous carbamazepine, 
PVP/carbamazepine co-melt and pure PVP. 
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From figure 6.22 one can see that PVP/carbamazepine has lower T1p H values than the 
crystalline sample, indicating a more mobile system. It can also be seen that the T1pH 
values are lower for the co-melt than for the amorphous, up to the change of slope 
observed for the amorphous drug. At this point, the co-melt has higher T1/ values, 
which seems to indicate a more stable system. It is also interesting to note that the 
change of slope observed for the co-melt happens at the same temperature as the 
minimum observed for the amorphous sample; this is probably just fortuitous, but it 
emphasises the fact that the co-melt is more stable than the amorphous drug on its 
own. 
When looking at the T 1 PH behaviour of the three co-melts, see figure 6.13, figure 6.17 
and figure 6.21, it is visible that there are some similarities as the three co-melts 
show negative slopes and go through a change of slope between 65°C and 85°C. 
However, the slope observed for PVP/carbamazepine is more pronounced than those 
for the other two co-melts, though it is not possible to assign this difference to any 
particular phenomenon. The comparison between the T1pH measurements of pure 
PVP, figure 6.4, and that of the PVP/carbamazepine co-melt, figure 6.21, shows that 
the relaxation ofthis co-melt is not dominated by the relaxation behaviour ofPVP. 
2/ Conclusions 
2.1 I Proton bandshape 
It has been seen that all three co-melts seemed to go through a transition between 
65°C and 1 05°C. The change in mobility observed seemed to be due to the PVP/drug 
co-melt going through its Tg. 
2.2/ T1H and T1/ measurements 
It was seen, from the T1H and T1/ experiments on the three co-melts, that the 
amorphisation process seemed to increase the mobility of the samples compared to 
' 
that for the crystalline samples. These experiments also showed that the presence of 
PVP seemed to slightly increase the mobility of the co-melt compared to that of the 
amorphous drug. 
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The T1H and T1/ measurements ofthe three co-melts did not seem to be dominated 
by the relaxation of pure PVP. A similar result, i.e. no evidence of an interaction for 
a drug/polymer physical mixture, was also observed by Di Martino et al.4 in their 
study of a physical mixture of PVP and ketoprofen. 
When looking at the T1H experiments, it was observed that the three co-melts 
behaved similarly in the fact that they all went through a maximum in T1H at around 
85°C. Nevertheless, in the case of the nifedipine and carbamazepine co-melts this 
maximum seemed to be a recovery from a broad minimum at about -30°C, whilst for 
PVP/indomethacin this minimum was around or below -70°C. The main point from 
the T 1 H study was that the maximum observed was at a higher temperature for the co-
melts than for the amorphous drugs, probably showing a greater stability of the 
former. 
The results obtained from the T1/ experiments showed that all three compounds 
went through a change in slope. This change happened around the same temperature 
for all three co-melts, and also at a higher temperature than the change in slope 
observed for their respective amorphous drugs. This seemed to indicate, as with the 
T1H study, that the co-melts were more stable than their respective amorphous drugs. 
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Chapte:r Seven: Conclusions 
11 Crystalline material 
The 1H and 13C solution-state NMR spectra of indomethacin, nifedipine and 
carbamazepine have been fully interpreted and this interpretation was in general 
agreement with the literature, except that, in the case of indomethacin, the 
assignments for C-2 and C-4 have been exchanged, and also gave a more detailed 
understanding for the aromatic region of carbamazepine. 
The crystalline forms of the studied molecules were confirmed to be of the y-form, 
modification I and modification III for indomethacin, nifedipine and carbamazepine 
respectively. 
The T1H measurements showed that indomethacin and nifedipine had different 
motional processes and confirmed a lack of conformational flexibility for 
carbamazepine. The T 1pH measurements showed that for indomethacin some internal 
motion was in place over the studied range of temperatures, i.e. -70°C to 80°C. In the 
case of nifedipine and carbamazepine it was not possible to obtain the T1p H values as 
they were too long to be measured without damage to the probe. 
The 13C SSNMR spectrum of indomethacin was slightly complicated by the 
quadrupolar effect caused by the chlorine atom present in the molecule and, from the 
investigation done on the effect, the following parameters were retrieved: 
- The true 13C chemical shift ofC-14 is 139 ppm± 0.2 ppm. 
- Jiso = ca. -43 Hz, which should be taken as a maximum magnitude. 
- x = -63 MHz, if ilJ is considered negligible. 
It was also shown that it was safe to assume that x is negative. 
2/ Amorphous material 
2.1/ Primary studies 
The three studied compounds could easily be made amorphous by a simple quench-
cooling process. It was observed that amorphous indomethacin was somewhat more 
stable than amorphous nifedipine and carbamazepine, as the former did not show 
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signs of recrystallisation up to a temperature of 80°C, whilst the other two 
compounds seem to recrystallise from a temperature of 65°C. However, some 
reversible process happened for indomethacin at 90°C. This process seemed to be 
related to an increased molecular mobility. All these results were obtained on the 
timescales of both XRPD and Be SSNMR experiments, apart from the reversible 
phenomenon at 90°C where only Be SSNMR was used. 
2.2/ 1H SSNMR 
It was observed, using the proton bandshapes, that indomethacin started to 
recrystallise above 1 00°C, whilst for nifedipine this started around 70°C and around 
75°C for carbamazepine. 
The T1H experiments showed that the amorphisation process seemed to increase the 
mobility of the sample. It was also noticed that this increase in mobility was larger 
for carbamazepine and nifedipine than for indomethacin, and that this probably 
caused the lower stability for the two former samples. The similarity in the T1H plots 
for indomethacin and carbamazepine, as well as the previous conclusion, seemed to 
show that comparison between the crystalline and amorphous materials should ·also 
be taken into account when trying to understand the stability of a given sample. The 
T1/ experiments confirmed the more mobile character of the amorphous forms 
compared to their crystalline counterparts. It was also seen that nifedipine and 
carbamazepine seemed more prone to recrystallisation than indomethacin, 
confirming the observations made with the T1 H experiments. 
3/ PVP/drug co-melts 
The Be SSNMR spectra of the crystalline and amorphous forms and of the solidified 
co-melts were compared. This showed that the method used to prepare the co-melts 
gave amorphous samples. 
The proton bandshape study showed that all three co-melts went through a transition 
between 65°C and 85°C, which was probably due to the Tg of the mixture. 
The T1H and T1p H experiments further confirmed the fact that amorphisation 
increased the mobility of a sample. It was also noticed from these experiments that 
the presence of PVP seemed to slightly increase the mobilitY of the co-melt 
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compared to the amorphous drug, and that the relaxation of PVP was not dominating 
the relaxation of the co-melts. Both relaxation experiments showed that the co-melts 
were more stable than the amorphous samples as the temperature at which noticeable 
change occurred was higher for the former. 
4/ Future work 
It would be interesting to develop a database of compounds establishing the way 
their mobility is influenced by their form: crystalline, amorphous or co-melt. It 
would also be interesting to look at the effect on the mobility of amorphous materials 
depending on the method used to prepare them. This would obviously have limits, 
depending upon how easy it would be to make a given compound amorphous using a 
specific method. One could also look at the effect of the polymer used in the co-
melts, as well as different ways to prepare the drug/polymer mixtures. 
This database should help deriving general principles which could be of great interest 
for pharmaceutical companies because, as stated in the introduction, amorphous 
compounds are generally more bioavailable than their crystalline counterparts. 
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Appendix 1: Temperature calibration of the static probe 
During the experiments (on the CMX200), the VT and purge gases were at 90 SCFH 
with nitrogen, and 110 SCFH with air. It is good to note that the purge gas has a very 
limited effect on the temperature as only the VT gas goes into the sample chamber. 
Therefore, it can be considered that the purge gas is having no effect on the 
temperature, and its value could be changed if needed. 
The temperature measurements were done using a sample of methanol put in a glass 
holder of 10 mm outer diameter. The spectra were acquired on a static sample. The 
actual temperature was calculated using the difference in peak positions (IL'l81) for 
each spectrum, using the following relation 1: 
T = 403K- (29.46K.ppm- 1) * IL'lc5l- (23.83K.ppm-2 ) * IL'lc51 2 
The plot of readout temperature versus sample temperature, figure 1, confirms that 
the two temperatures are indistinguishable (within experimental error). This shows 
that the thermocouple used to measure the temperature is well calibrated over the 
temperature range examined. The standard deviation of the difference between the 
reading and "real" temperature is 0.96. This means that the readout temperature can 
be taken as the actual sample temperature ± 1.0°C when using this probe. The raw 
data are shown in table 1. 
1 Bielecki A., Burum D.P., J Magn. Reson. Ser. A, 1995, 116, p. 215 
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Figure 1: Reading versus calculated temperature plot of the VT calibration of the 
static probe, mounted with the 10 mm coil, on the CMX 200. 
1~81 /ppm Reading Temperature I oc Calculated Temperature /°C 
1.565 25 25.53 
1.653 15 16.19 
1.796 0 0.22 
1.957 -20 -18.92 
2.131 -40 -41.00 
2.270 -60 -59.67 
2.420 -80 -80.85 
2.133 -40 -41.26 
1.573 25 24.70 
1.420 40 40.12 
1.294 50 51.98 
1.319 50 49.68 
Table 1: Raw data for the VT calibration of the static probe, mounted with the 10 
mm coil, on the CMX 200. 
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Appendix 2: FTIR of crystalline indomethacin. 
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Appendix 3: XRPD of crystalline nifedipine. 
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Appendix 4: FTIR of crystalline carbamazepine. 
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Appendix 5: COSY spectrum of nifedipine, in d6-DMSO, showing the 
high-frequency part. 
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Appendix 6: HSQC spectrum ofnifedipine, in d6-DMSO. 
1/ 1 11 11 I L I 
''' ' '1 ' ''' ' '' ' '1 ' ''' ' ''''1'''' ' '' ' '1 
180 160 140 120 100 80 60 40 20 
F1 (ppm) 
Appendix 7: HMBC spectrum ofnifedipine, in d6-DMSO. 
163 
Appendices 
1H database 'H experimental 
Atom Chemical shift I Number of Atom Chemical shift I 
number ppm matches number pQm 
2', 6' 2.25 13 2', 6' 2.25 
3", 5" 3.63 15 3", 5" 3.45 
4 4.98 85 4 5.49 
9 7.34 13958 10 7.35 
8 7.53 45102 8 7.46 
10 7.62 6 9 7.59 
11 8.04 11 11 7.70 
NH 8.53 13 NH 9.03 
uc database uc experimental 
Atom Chemical shift I Number of Atom Chemical shift I 
number ppm matches number m?_m 
2', 6' 19.4 2 2', 6' 18.9 
4 34.9 16 4 34.6 
3", 5" 50.8 1 3", 5" 51.3 
3, 5 104.4 2 3, 5 102.0 
11 123.5 88 11 124.3 
8 126.7 1009 10 128.1 
9 127.2 213 8 131.3 
10 129.5 51 9 133.9 
7 137.9 2 7 142.7 
2,6 143.9 2 2,6 147.2 
12 148.8 2 12 147.9 
3', 5' 168.1 1 3', 5' 167.6 
Appendix 8: Comparison between the experimental results and the database 
predictions for the assignment of 1 H and 13C in the case of nifedipine. 
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Appendix 9: COSY spectrum of carbamazepine, in CDCb, showing the 
high-frequency part. 
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Appendix 10: HSQC spectrum of carbamazepine, in CDCI3, showing the 
high-frequency part. 
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Appendix 11: HMBC spectrum of carbamazepine, in CDCh, showing the 
high-frequency part. 
167 
Appendices 
1H database 1 H experimental 
Atom Chemical shift I Number of Atom Chemical shift I 
number ppm hits number ppm 
NH2 5.48 1 NH2 4.82 
4, 11 6.82 23 7, 8 6.94 
5, 10 7.17 23 4, 11 7.33 
3, 12 7.23 106 5, 10 7.37 
7, 8 7.29 220 3, 12 7.43 
2, 13 7.30 117 2, 13 7.47 
13C database ..,C experimental 
Atom Chemical shift I Number of Atom Chemical shift I 
number ppm hits number ppm 
2, 13 118.4 1 4, 11 128.0 
4, 11 128.2 6 2, 13 129.0 
7,8 129.2 6 3, 12 129.7 
5, 10 130.5 6 5, 10 129.8 
3, 12 130.8 1 7, 8 130.7 
6, 9 137.1 6 6,9 135.2 
1, 14 139.3 1 1, 14 140.2 
15 159.2 7 15 157.5 
Appendix 12: Comparison between the experimental results and the database 
predictions for the assignment of 1H and Be in the case of carbamazepine. 
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Appendix 13: Theory versus experimental for indomethacin, at 50.32 MHz, Be 
frequency, ofC-14, J =-43Hz and x = -63 MHz. 
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-Experiment 
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Appendix 14: Theory versus experimental for indomethacin, at 75.43 MHz, 13C 
frequency, ofC-14, J =-43Hz and x = -63 MHz. 
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Appendix 15: Theory versus experimental for indomethacin, at 125.68 MHz, 13C 
frequency, ofC-14, J =-43Hz and x = -63 MHz. 
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-Experiment 
-Theory 
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Appendix 16: Theory versus experimental for indomethacin, at 201.12 MHz, 13C 
frequency, ofC-14, J =-43Hz and x = -63 MHz. 
Temperature I °C TtH Is TtpH I ms 
-70 0.7 850.0 
-50 1.1 924 
-30 1.9 323 
-10 2.9 65.2 
10 4.7 22 
25 5.8 20.8 
30 6.7 24.5 
40 8.1 39.2 
50 9 60.8 
60 11.5 97.4 
80 12.5 214.6 
Appendix 17: TtH and TtpH raw data obtained as a function of temperature for 
crystalline indomethacin. 
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Temperature I oc T,H Is 
-70 12.7 
-50 15.3 
-30 18.0 
-10 20.9 
10 24.9 
25 26.0 
30 26.7 
40 26.9 
50 27.9 
60 29.1 
70 29.6 
80 29.1 
100 30.2 
Appendix 18: T 1H and T1pH raw data obtained as a function of temperature for 
crystalline nifedipine. At each temperature T1pH was too long to be measured. 
Temperature I oc T,H Is T1pH lms 
-70 404.6 Too long 
-40 331.3 Too long 
-10 340.5 Too long 
10 438.7 Too long 
25 348.1 Too long 
40 311.6 Too long 
55 355.7 Too long 
75 407.4 726.7 
95 412.8 173.6 
Appendix 19: T 1H and T1pH raw data obtained as a function of temperature for 
crystalline carbarnazepine. 
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300MHz 200MHz 
Temperature I °C TlH Is 
TtpH I ms 
Temperature I °C TJH Is T1pH I ms 
-70 1.6 64 -70 0.9 86.2 
-50 2.1 57 -50 1.0 69.7 
-30 3.0 52 -30 1.1 56.9 
-10 4.3 46 -10 1.5 46.3 
10 6.2 42 10 2.1 39.1 
22 7.8 41 22 2.6 36.1 
30 8.6 40 30 2.8 34.1 
40 9.3 37 40 2.9 28.5 
50 7.9 24 50 2.8 19.6 
60 7.9 8.8 60 2.6 8.9 
80 6.1 1.2 80 1.3 3.0 
300MHz 200MHz 
Temperature I °C TlH Is TtpHims Temperature I °C T)H Is TtpH I ms 
-70 1.59 72.1 -70 0.5 121 
-60 1.77 70 -50 0.8 91.2 
-50 2.09 66.9 -30 1.1 76.3 
-40 2.47 62.7 0 2 57.6 
-30 3.01 58.3 20 3.1 51.2 
-20 3.66 54.2 30 3.7 51.1 
-10 4.52 50.2 40 3.6 37.1 
0 5.48 47.8 50 3.2 23 .6 
10 6.53 45 .5 60 3.3 9.8 
20 7.59 44.6 80 2.3 1.2 
30 8.81 43 .7 90 1.6 1.1 
40 9.24 37 100 1.2 2.9 
45 8.26 29.8 
50 7.9 22.3 
60 7.93 7.5 
70 7.44 1.9 
75 7.07 1.3 
80 6.45 1.2 
90 5.23 1.6 
100 3 48 32 
·J li Appendix 20: T 1 and TIp raw data obtained as a function of temperature for 
amorphous indomethacin. The colours are the same as for the plots. 
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300MHz 200MHz 
Temperature I °C Tt" Is Temperature I oc Tt" Is 
-70 8.79 -70 4.3 
-50 10.8 -50 5.7 
-30 12.3 -30 6.7 
-10 13 .7 -10 7.7 
10 16.4 15 8.8 
20 18.7 25 10.1 
30 20.2 30 10.6 
40 21.7 40 10.6 
50 19.2 50 9.5 
60 17.1 60 8.4 
70 14.1 
300MHz 
Temperature I °C Tt" Is 
-60 10.5 
-20 17.8 
0 20.9 
20 24.4 
30 26.2 
40 25.2 
60 17.7 
Appendix 21: TtH raw data obtained as a function of temperature for amorphous 
nifedipine. The colours are the same as for the plots. 
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300MH.z 200MH.z 
Temperature I °C T1pt1 I ms Temperature I °C T1pt1 I ms 
-60 161 -70 136.8 
-40 148 -50 116.8 
-20 142 -30 114.3 
0 135 -10 92.9 
10 139 10 97.2 
20 145 22 79.1 
30 129 30 76.0 
40 98 40 54.9 
50 39 50 28 .9 
60 9.0 60 9.8 
65 4.1 
200MHz 
300MH.z Temperature I °C T1pt1lms 
Temperature I °C T1pH I ms -70 359.5 
-60 138 -40 223 .3 
-20 130 -10 216.8 
0 123 20 148.1 
20 126 30 101.2 
30 124 40 73.6 
50 35.7 
60 10.8 
Appendix 22: T1pH raw data obtained as a function of temperature for amorphous 
nifedipine. The colours are the same as for the plots. 
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200MHz 200MHz 
Temperature I °C TIH Is T1pH I ms Temperature I oc TIH Is T1pH I ms 
-70 7.6 951.3 -70 9.4 754.3 
-30 5.6 286.9 -30 7.0 292.3 
10 6.7 88.6 10 7.5 91.0 
25 6.6 60.0 25 7.5 56.4 
35 6.9 45 .9 35 7.9 42.5 
45 7.3 29.8 45 8.3 28.5 
55 7.4 16.7 55 8.3 16.4 
65 6.7 7.9 65 7.9 7.7 
75 5.9 3.3 75 7.1 3.0 
85 4.9 2.9 85 5.3 3.6 
105 
-
5.6 105 - 7.2 
Appendix 23: T1H and T1pH raw data obtained as a function of temperature for 
amorphous carbamazepine. The colours are the same as for the plots. 
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Temperature I oc TIH Is T1pH I ms 
-20 5.7 6.2 
-10 5.1 6.5 
0 4.4 7.3 
10 3.9 9.6 
20 3.5 11.2 
30 2.1 14.3 
40 2.1 14.1 
50 2.1 20.6 
60 2.4 19.9 
70 2.7 21.8 
80 3.2 22 
90 3.8 21.8 
100 4.2 18.7 
110 5.0 15.4 
120 5.6 13.8 
130 6.2 11.7 
140 7.0 10.3 
Appendix 24: T1H and T1pH raw data obtained as a function of temperature for PVP 
on its own2• 
2 D. C. Apperley. GlaxoWellcome- Amorphous drug project, Unpublished. 
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300MHz 200MHz 
Temperature I °C TtH Is T1pH I ms Temperature I °C Tt 11 1s Ttp11 I ms 
-20 3.2 21.1 -70 1.8 107.3 
-10 3.2 18.8 -40 2.3 80.6 
0 3.4 17.5 -10 3.0 59.1 
10 3.6 15.8 15 4.1 47.7 
20 3.9 16.0 40 5.0 40.9 
30 3.5 15 .9 65 6.0 38.3 
40 3.6 16.0 85 6.1 25.1 
50 3.8 16.2 100 5.9 12.6 
60 4.2 15 .5 110 5.4 4.7 
70 5.2 16.1 120 5.1 2.2 
80 6.6 14.5 140 4.0 0.9 
90 6.8 10.2 
100 6.9 6.1 200MHz 
110 7.4 2.6 Temperature I °C T1 11 Is T1p11 I ms 
120 7.3 1.5 -70 1.8 97.6 
130 6.4 1.2 -30 2.4 63.4 
140 5.3 - 10 3.5 41.5 
40 4.4 35.8 
65 5.6 34.3 
85 6.0 24.8 
100 5.8 13 .0 
110 5.4 6.8 
120 5.3 2.5 
140 3.7 0.9 
Appendix 25: T 1 H and T tp H raw data obtained as a function of temperature for the 
PVPiindomethacin co-melt. The colours are the same as for the plots. 
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300MHz 200MHz 
Temperature I oc Ttls T1pH I ms Temperature I °C T1n Is T1pn I ms 
-20 4.0 29.9 -70 3.3 96.0 
-10 3.9 27.1 -40 3.0 82.9 
0 4.0 25 .9 0 3.5 71.8 
10 4.0 25.9 40 4.4 62.0 
20 4.4 26.5 65 5.4 51.3 
30 3.8 27.9 85 5.8 30.3 
40 3.7 30.4 100 5.5 10.2 
50 4.0 31.9 110 5.2 5.7 
60 4.5 26.6 120 4.9 2.8 
70 4.8 19.9 140 3.7 1.0 
80 4.9 13 .1 
90 4.6 6.9 200MHz 
100 4.9 4.3 Temperature I °C T1nls T1pn I ms 
110 5.3 2.8 -70 3.1 93 .5 
120 5.9 2.1 -30 2.9 75 .7 
130 5.4 2.2 10 3.7 62.6 
140 4.2 3.2 40 4.2 56.3 
65 5.4 47.2 
85 5.6 27.3 
100 5.1 9.1 
110 4.7 3.5 
120 4.4 1.9 
140 3.1 1.0 
Appendix 2(j: T/1 and T1pH raw data obtained as a function of temperature for the 
PVPinifedipine co-melt. The colours are the same as for the plots. 
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200MHz 200MHz 
Temperature I °C Ttl s T1ptt I ms Temperature I °C Ttls T1pH I ms 
-70 6.2 248.3 -70 5.8 121.6 
-30 4.9 134.7 -30 4.8 69.5 
10 5.3 59.4 10 5.2 33.2 
40 6.2 31.5 40 5.7 23.4 
65 9.0 20.6 65 7.6 17.9 
85 10.3 12.2 85 7.8 11.2 
100 9.3 7.6 100 7.3 5.0 
110 7.8 5.1 110 6.4 2.8 
120 6.4 2.3 120 5.7 1.7 
140 3.9 1.1 140 3.6 0.9 
Appendix 27: T1H and T1pH raw data obtained as a function of temperature for the 
PVPicarbamazepine co-melt. The colours are the same as for the plots. 
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Appendix 28: GHbenclamide 
Three different samples of glibenclamide, figure 2, have been given, by James 
Patterson. One was a crystalline sample, whilst the other two were prepared in order 
to make them amorphous, i.e. by milling and by quench-cooling. It was needed to 
find out which method of amorphisation was the most efficient for this compound. 
The 13C SSNMR spectra of each of the three samples was acquired and the result is 
shown in figure 3. 
0 
Cl 
Figure 2: Glibenclamide. 
N 
H 
It is clearly visible from figure 3 that both methods gave an amorphous compound. 
However, the milling technique seemed to give a sample that is not as amorphous as 
the quench-cooled technique. This showed that for this specific compound it would 
be better to use the quench-cooling technique in order to obtain an amorphous 
sample. 
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100 ppm 
50 
50 
Glibenclamide quench-cooled 
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Figure 3: 13C CPMAS of glibenclamide obtained at 50.32 MHz, 13C frequency. 
181 
Appendices 
Appendix 29: Talks, posters and publication 
Talks and posters: 
4th July 2002: 
September 2002: 
Group meeting involving personnel form GSK and staff members 
form University of London School of Pharmacy. 
Participant in the Anglo-French Meeting on Magnetic Resonance 
Spectroscopy conference in Southampton. 
22nd September 2003: Talk on my Ph.D. project at GSK, Stevenage. 
Title: The study of relaxation times of amorphous Indomethacin and 
Nifedipine using solid-state NMR. 
23rd September 2003: Group meeting involving personnel form GSK and staff members 
form University of London School of Pharmacy. 
25th June 2004: 
14th July 2004: 
September 2004: 
Article published: 
Final year departmental talk in the Chemistry department at Durham 
University. 
Title: The study of relaxation times of amorphous Indomethacin and 
Nifedipine using solid-state NMR. 
Presentation of my Ph. D. project at GSK, Harlow. 
Title: The study of relaxation times of amorphous Indomethacin and 
Nifedipine using solid-state NMR. 
Poster presentation at the Anglo-German Magnetic Resonance 
Spectroscopy conference in Aachen, Germany. 
Poster title: Probing the mobility of pharmaceutical systems using 
solid-state NMR relaxation times 
D. C. Apperley, A. H. Forster, R. Fournier, R. K. Harris, P. Hodgkinson, R. W. 
Lancaster and T. Rades. Characterisation of indomethacin and nifedipine using 
variable-temperature solid-state NMR. Magn. Res. Chern .. 43: 881-892 (2005). 
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